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ABSTRACT 
Jason Douglas Rupp 
 
NEURAL CORRELATES AND PROGRESSION OF SACCADE IMPAIRMENT IN 
PREMANIFEST AND MANIFEST HUNTINGTON DISEASE 
 
Huntington disease (HD) is an autosomal dominant disorder characterized by progressive 
decline of motor, cognitive, and behavioral function. Saccades (rapid, gaze-shifting eye 
movements) are affected before a clinical diagnosis of HD is certain (i.e. during the 
premanifest period of the disease). Fundamental questions remain regarding the neural 
substrates of abnormal saccades and the course of premanifest disease. This work 
addressed these questions using magnetic resonance imaging (MRI) and a longitudinal 
study of premanifest disease progression. 
 
Gray matter atrophy is a characteristic of HD that can be reliably detected during the 
premanifest period, but it is not known how such changes influence saccadic behavior.  
We evaluated antisaccades (AS) and memory guided saccades (MG) in premanifest and 
manifest HD, then tested for associations between impaired saccadic measures and gray 
matter atrophy in brain regions involved in these saccadic tasks. The results suggest that 
slowed vertical AS responses indicate cortical and subcortical atrophy and may be a 
noninvasive marker of atrophic changes in the brain. 
 
viii 
 
We also investigated the brain changes that underlie AS impairment using an event-
related AS design with functional MRI (fMRI). We found that, in premanifest and 
manifest HD, blood oxygenation level dependent (BOLD) response was abnormally 
absent in the pre-supplementary motor area and dorsal anterior cingulate cortex following 
incorrect AS responses. These results are the first to suggest that abnormalities in an 
error-related response network underlie early disease-related saccadic changes, and they 
emphasize the important influence of regions outside the striatum and frontal cortex in 
disease manifestations. 
 
Though saccadic abnormalities have been repeatedly observed cross sectionally, they 
have not yet been studied longitudinally in premanifest HD. We found different patterns 
of decline; for some measures the rate of decline increased as individuals approached 
onset, while for others the rate was constant throughout the premanifest period. These 
results establish the effectiveness of saccadic measures in tracking premanifest disease 
progression, and argue for their use in clinical trials.  
 
Together, these studies establish the utility of saccade measures as a marker of HD 
neurodegeneration and suggest that they would be a valuable component of batteries 
evaluating the efficacy of neuroprotective therapies. 
 
Tatiana Foroud, PhD, Chair 
ix 
 
TABLE OF CONTENTS 
 
List of Tables ................................................................................................................xi 
List of Figures ...............................................................................................................xii 
List of Abbreviations ....................................................................................................xiii 
I. Introduction 
 A. Genetics of Huntington disease....................................................................1 
 B. Function of huntingtin protein......................................................................3 
 C. Clinical Characteristics of Huntington disease ............................................5 
 D. Magnetic resonance imaging in Huntington disease ....................................10 
 E. Saccade signaling pathways in the brain ......................................................15 
 F. Biomarkers of Huntington disease................................................................19 
 G. Statement of Purpose ...................................................................................20 
II. Vertical antisaccade latency tracks gray matter atrophy in premanifest 
and early manifest Huntington disease 
 A. Introduction ..................................................................................................22 
 B. Methods ........................................................................................................23 
 C. Results ..........................................................................................................26 
 D. Discussion ....................................................................................................34 
III. Abnormal error-related antisaccade activation in premanifest and early 
manifest Huntington disease 
 A. Introduction ..................................................................................................38 
 B. Methods ........................................................................................................40 
 C. Results ..........................................................................................................45 
x 
 
 D. Discussion ....................................................................................................55 
IV. Progression in prediagnostic Huntington disease 
 A. Introduction ..................................................................................................60 
 B. Methods ........................................................................................................61 
 C. Results ..........................................................................................................65 
 D. Discussion ....................................................................................................74 
V. Summary ..................................................................................................................78 
References .....................................................................................................................84 
Curriculum Vitae 
  
xi 
 
LIST OF TABLES 
 
1: Association between CAG repeats and clinical outcomes ........................................1 
2: Summary of fMRI studies in premanifest and manifest HD ....................................12 
3: Participant demographics (saccades and structural imaging)  ..................................27 
4: Group differences in saccade performance ...............................................................29 
5: Gray matter atrophy in saccade-related brain regions ..............................................31 
6: Correlation coefficients (p values) of significant associations between 
measures of brain atrophy and saccade impairment .................................................32 
7: Participant demographics (functional imaging)  .......................................................46 
8: ROI locations and sizes as defined by CAG- controls, and non-zero 
linear regression parameter estimates and p values (with preHD as the 
reference group) from the modeling of ROI-extracted mean activations ................49 
9: Participant demographics (longitudinal progression)  ..............................................65 
10: Results of repeated measure mixed model .............................................................71 
11: Results of ANCOVA with three groups .................................................................73 
 
  
xii 
 
LIST OF FIGURES 
 
1: Basal ganglia signaling pathways .............................................................................6 
2: Saccadic tasks and target locations ...........................................................................15 
3: Schematic of cortical saccade pathways ...................................................................17 
4: Plots of vertical AS latency and structural measures ................................................33 
5: The fMRI task protocol.............................................................................................42 
6: Performance on the PS and AS tasks ........................................................................47 
7: Functional ROIs defined in CAG- participants for each saccade 
comparison ....................................................................................................................53 
8: BOLD response [incorrect AS > correct AS] as a function of the 
percentage of incorrect AS............................................................................................54 
9: Performance of CAG+ subjects ................................................................................68 
10: Temporal appearance of changes in premanifest HD .............................................82 
 
  
xiii 
 
LIST OF ABBREVIATIONS 
 
ACC Anterior cingulate 
cortex 
ANCOVA Analysis of covariance 
AS Antisaccade 
BDNF Brain derived 
neurotropic factor 
BOLD Blood oxygenation level 
dependent 
cACC Caudal anterior 
cingulate cortex 
CAG- Unexpanded number of 
CAG repeats (≤27 
repeats) 
CAG+ Expanded number of 
CAG repeats (≥39 
repeats) 
CES-D Center for 
Epidemiologic Studies 
Depression Scale 
cMFG Caudal middle frontal 
gyrus 
CVLT California Verbal 
Learning Test 
dACC Dorsal anterior 
cingulate cortex 
DLPFC Dorsolateral prefrontal 
cortex 
DTI Diffusion tensor 
imaging 
ERN Event related negativity 
ERP Event related potential 
FEF Frontal eye fields 
fMRI Functional magnetic 
resonance imaging 
FXS Fragile X syndrome 
FXTAS Fragile X-associated 
tremor ataxia syndrome 
GPe Globus pallidus externa 
GPi Globus pallidus interna 
HD Huntington disease 
ICV Intracranial volume 
IFG Inferior frontal gyrus 
IPL Inferior parietal lobule 
IPS Intraparietal sulcus 
MG Memory guided saccade 
MG1 Memory guided, simple 
task (see MGs) 
MG2 Memory guided, 
complex task (see MGc) 
MGc Memory guided, 
complex task 
MGi Memory guided, 
intermediate task 
MGs Memory guided, simple 
task 
MNI Minnesota Neurological 
Institute 
MPRAGE Magnetization prepared 
rapid gradient echo  
MRI Magnetic resonance 
imaging 
MT Movement time 
MTG Middle temporal gyrus 
NC Controls (see CAG-) 
PCC Posterior cingulate 
cortex 
PEF Parietal eye fields 
PFC Prefrontal cortex 
PolyQ Polyglutamine tract 
PreHD Premanifest HD 
Pre-SMA Pre-supplementary 
motor area 
PS Prosaccade 
rACC Rostral anterior 
cingulate cortex 
rMFG Rostral middle frontal 
gyrus 
ROI Region of interest 
RT Reaction time 
xiv 
 
SDMT Symbol Digit 
Modalities Test 
SEF Supplementary eye 
fields 
SFG Superior frontal gyrus 
SMA Supplementary motor 
area 
SNpr Substantia nigra pars 
reticulata 
SPL Superior parietal lobule 
STN Subthalamic nucleus 
TTO Time to onset 
UHDRS Unified Huntington 
Disease Rating Scale 
WAIS-R Weschler Adult 
Intelligence Scale - 
Revised 
 
1 
 
I. Introduction 
 
A. Genetics of Huntington disease 
 
Huntington disease (HD) is an autosomal 
dominant disorder caused by an abnormal 
expansion of a CAG trinucleotide repeat in 
exon 1 of the huntingtin gene.
1
 Current 
recommendations (Table 1) suggest that 
thirty-five or fewer CAG repeats should be 
considered normal (CAG-), and that more 
than 35 repeats in one allele can lead to 
disease
2
 (CAG+). However, some 
additional nuances should be noted. First, 
individuals with 27-35 repeats, while not at 
risk for developing the disease, have an increased risk of further expansion during 
meiosis and, thus, passing on a disease-causing allele to their children. However, some 
recent reports indicate that HD may result from alleles with between 29 and 35 repeats,
3-6
 
though these cases appear to be rare. Second, there is reduced penetrance of the disease in 
individuals with 36-39 repeats,
7
 while the disease is fully penetrant in those with more 
than 39 repeats. 
 
The identification of the gene and responsible mutation makes presymptomatic gene 
testing possible. Prior to the availability of testing, 40-80% of at-risk individuals 
expressed intent to use the test once it became available,
8
 though the actual use is only 
10% in Indiana
9
 and ranges from 4-24% worldwide.
10
  Among those who did seek 
testing, the most common reasons cited were to relieve the anxiety associated with 
uncertainty, to plan for the future (including family planning), and to inform their 
children.
10-12
  Perhaps not surprisingly, both positive (CAG expansion present) and 
negative (CAG expansion not present) test results lead to reports of distress, though at 
different times.
10
  Distress immediately followed positive tests, but was experienced at 
Table 1. Association between CAG 
repeats and clinical outcomes. 
Number of 
CAG Repeats Clinical Outcome 
< 27 No disease 
27 – 35 No disease, possibly 
expanded in offspring 
36 – 39 Possible disease 
(reduced penetrance) 
> 39 Disease (full 
penetrance) 
 
2 
 
around 6 months following negative tests. By one year post-testing, distress in those who 
had received a positive test had returned to baseline, while a slight decrease in distress 
was found in those with a negative test. One important caveat is that individual responses 
will greatly vary, and plans should be put in place early for both pre- and post-testing 
counseling.
13
 
 
The genetic phenomenon of anticipation is seen in HD. Anticipation is the finding that 
disease symptoms occur earlier in subsequent generations. One important observation in 
understanding the mechanisms of anticipation in HD is that the size of the CAG 
expansion explains about 70% of the variability in age of disease onset.
14
  A second 
observation that helps to explain anticipation in HD is that the size of the repeat tends to 
expand in abnormally large alleles. Zühlke et al.
15
 found a change in repeat size in 72% 
of 54 transmissions involving an expanded allele (>40 repeats), while only 0.5% of 431 
normal allele transmissions resulted in a change. The changes observed in the expanded 
allele were classified as either small variations (±3 repeats) or large expansions (>4 
repeats). While the percentage of altered transmissions was the same in both the maternal 
and paternal lines, all 10 large expansions (4-28 repeats) resulted from paternal 
transmission. While studies in mice suggest that this expansion occurs in post-meiotic 
cells,
16
 a post-mortem human study found evidence of substantial pre- and post-meiotic 
expansion.
17
  Interestingly, post-mitotic expansion of the CAG repeat in striatal neurons 
has been described in mouse models
18
 and may help explain some of the variability seen 
in HD. 
 
The pathogenic repeat expansion is not unique to HD; at least 18 other nucleotide repeat 
expansion disorders have been identified.
19
  Most involve trinucleotide repeats, though 
tetra- and pentanucleotide repeat sequences can also be pathologically expanded. As is 
the case in HD, larger expansions are more unstable and thus produce even larger 
expansions, resulting in anticipation. The expansion seems to occur through a mechanism 
that involves stalling and restarting of the replication fork.
20
 Though it is not known why, 
all 9 CAG repeat expansion disorders are neurodegenerative. The pathogenic 
mechanisms of disease include a loss of function at the protein level and a gain of 
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function at either the RNA or protein level. HD is an example of protein gain of function 
and will be discussed later. The other mechanisms are exemplified by the FMR1 gene 
that leads to fragile X syndrome (FXS) or fragile X-associated tremor ataxia syndrome 
(FXTAS) depending on the number of CGG repeats. A normal allele has 5-55 repeats in 
the 5’ untranslated region of the gene. If there are more than 200 repeats the gene is 
transcriptionally silenced via methylation and deacetylation. Fewer transcripts leads to a 
loss of protein, and the clinical result is FXS.
21;22
  However, if the expansion is in an 
intermediate range (55-200 repeats), a toxic mRNA is transcribed. This mRNA binds 
proteins important for post-transcriptional modification and sequesters them in 
intranuclear inclusions,
23;24
 leading to the clinically distinct disease FXTAS. 
 
While modifier genes do not appear to affect the presence or absence of HD, they have 
been shown to affect the symptoms and progression of the disease. One such modifier is 
the normal allele of the huntingtin gene. Aziz et al.
25
 found that, in individuals with a 
relatively small number of repeats in the expanded allele (closer to 40), age of onset was 
delayed and the severity of motor and cognitive symptoms was reduced when the normal 
allele was relatively small (closer to 10); when the number of repeats in the expanded 
allele was large, age of onset was delayed and symptom severity was reduced when the 
normal allele was relatively large. Eight other genes have also been proposed to influence 
age of onset (GRIK2,
26-29
 APOE,
30;31
 TCERG1,
32
 UCHL1,
29
 TP53,
33
 DFFB,
33
 GRIN2B,
34
 
GRIN2A
34
), though a study in a Venezuelan kindred confirmed only the effect of 
GRIN2A.
35
 
 
B. Function of huntingtin protein 
 
The CAG repeat is translated into a poly-glutamine (polyQ) tract in the huntingtin 
protein. Unfortunately, the mechanism by which this polyQ tract produces disease is 
unknown. Most studies point to a toxic gain of function in the mutant protein,
36-44
 though 
haploinsufficiency may also play a role in the development of symptoms.
44
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Wild-type huntingtin appears to play many roles influenced by developmental timing, 
cell type, and intracellular location.
45
 The protein is quite large (3144 amino acids, 348 
kD), though it does not share sequence homology with other proteins.
45
  Furthermore, it 
contains only a few known sequence motifs and no structural domains with known 
function.
45
  Huntingtin is ubiquitously expressed in neural and non-neural tissues, with 
highest expression in neurons and the testes.
46-48
 A double-knockout is embryonic lethal 
in mouse models prior to gastrulation.
38-40
  However, there are no apparent developmental 
defects in individuals homozygous for the expansion,
49;50
 suggesting that the polyQ tract 
does not exert its deleterious effects during the earliest stages of development. Following 
gastrulation, decreased amounts of huntingtin have been shown to adversely affect 
neurogenesis
41;51
 and maintenance of neuronal identity
52
 in mice, but once again the 
polyQ tract does not appear to play a role in these functions. 
 
Because HD is neurodegenerative, the role of normal huntingtin in neurons has received 
particular attention. It appears to have protective effects in response to a variety of 
apoptotic stimuli including serum deprivation, mitochondrial toxins, death genes, 
ischemic injury, and excitotoxicity.
53-55
  This property is conferred by the N-terminal 548 
amino acids.
53
  Another role for huntingtin in the neuron is that it appears to simulate the 
production of brain-derived neurotrophic factor
56;57
(BDNF). BDNF is an important 
neurotrophin for striatal cells; it is produced in cortical neurons
58;59
 and trafficked along 
cortico-striatal afferents to striatal targets.
60-62
  BDNF also reduces excitotoxic effects by 
controlling glutamate release at the cortico-striatal synapse.
63-66
 
 
Huntingtin also appears to play a role in vesicular trafficking. It facilitates the transport of 
BDNF and mitochondria along axonal microtubules.
67;68
  The protein also plays a role in 
endo- and exocytosis at the synaptic terminal; it associates with clathrin via huntingtin-
interacting protein 1
69-72
 (HIP-1). Huntingtin also associates with postsynaptic density 
protein 95 (PSD-95), thereby reducing NMDA-mediated excitotoxic effects.
73
 
 
Huntingtin has functional nuclear export and nuclear localization signals. Given that the 
protein is found both in and around the nucleus, it may play a role in transporting 
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molecules out of the nucleus.
74
  Also, the wild-type polyQ tract binds many transcription 
factors that also contain a glutamine-rich domain.
75-78
  Further supporting the role of 
huntingtin in transcriptional regulation is the observation of early gene-expression 
changes in models of HD.
79
 
 
While it is not yet clear how mutant huntingtin causes neurodegeneration, understanding 
its myriad normal functions can give clues as to potential sources of pathogenesis. 
Furthermore, it has been observed that huntingtin is cleaved and that the N-terminal 
fragment accumulates in insoluble aggregates,
80
 though it is not clear if these aggregates 
play a role in neurodegeneration.
79
  In summary, the pathogenesis of HD is not clear, 
though some combination of aggregate formation, excitotoxicity, oxidative stress, and 
metabolic dysfunction are likely causes. 
 
C. Clinical characteristics of Huntington disease 
 
HD typically has a delayed onset; the average age of disease onset is 40 years, although 
onset has occurred as early as age 2 and as late as age 80.
81;82
 The size of the CAG 
expansion is negatively correlated with the age of disease onset
83;84
 and explains up to 
70% of the variability of age of onset.
14
  This observation has led to the development of 
models to estimate the number of years prior to onset and the probability of onset within 
a given number of years.
84
 HD progresses steadily until death, typically 10-20 years after 
diagnosis,
85
 which often occurs subsequent to falls, dysphagia, or aspiration.
86
 
 
Diagnosis of HD is made using the Unified Huntington Disease Rating Scale-99
87
 
(UHDRS), an instrument that relies heavily on the motor manifestations of the disease. 
Dentatorubro-pallidoluysian atrophy, Huntington’s disease-like syndromes 1-3, familial 
prion disease, Friedrich’s ataxia, spinocrebellar ataxias, chorea-acanthocytosis, and 
Wilson’s disease and other iron-accumulation disorders are phenotypically 
indistinguishable from HD and must be considered as part of the differential 
diagnosis,
86;88;89
 though a gene test showing the CAG expansion in the huntingtin gene is 
confirmatory. The UHDRS asks the neurologist, 
6 
 
To what degree are you confident that this person meets the 
operational definition of the unequivoc0al presence of an otherwise 
unexplained extrapyramidal movement disorder (e.g., chorea, 
dystonia, bradykinesia, rigidity) in a person at risk for HD? 
0 = normal (no abnormalities) 
1 = non-specific motor abnormalities (less than 50% confidence) 
2 = motor abnormalities that may be signs of HD (50-89% 
confidence) 
3 = motor abnormalities that are likely signs of HD (90-98% 
confidence) 
4 = motor abnormalities that are unequivocal signs of HD (≥99% 
confidence) 
Before the unequivocal manifestation of HD (response of 4 to the above question), CAG+ 
individuals are considered to be in the premanifest period of the disease, during which 
varying degrees of motor, cognitive, and behavioral abnormalities can be detected.  
 
1. Motor abnormalities in Huntington disease 
 
Though it had been described previously,
86
 George Huntington’s extensive description of 
the disease in 1872
90
 led to an enduring association with his name. Huntington focused 
on the choreic movements, and the disease was referred to as Huntington’s chorea for 
several years. Chorea can be explained by the preferential loss of indirect pathway 
neurons in the striatum
91-93
  
(Figure 1). This leads to 
decreased inhibitory output to 
globus pallidus externa (GPe), 
increased inhibitory output from 
GPe to subthalamic nucleus 
(STN), and subsequent decreased 
excitatory output from STN to 
globus pallidus interna (GPi) and 
substantia nigra pars reticulata 
(SNpr). Decreased stimulation of 
GPi/SNpr leads to a loss of 
Figure 1. Basal ganglia signaling pathways. The 
loss of indirect pathway striatal neurons (dotted red 
line) leads to chorea in HD. Green: excitatory; red: 
inhibitory. 
 
7 
 
inhibitory output to the thalamus, which in turn excites the cortex and produces unwanted 
motor output.  
 
While chorea continues to play an important role in diagnosis, it is not a reliable marker 
of disease severity.
94;95
  This is partly explained by the observation that chorea often 
lessens in the late stages of the disease as dystonia and rigidity become more prominent 
features of HD.
94;95
 Other motor abnormalities include incoordination and 
impersistence
86;96
 (e.g. the inability to maintain the force of a voluntary muscle 
contraction). In the premanifest period, the loss of fine motor skills and delayed reaction 
times are prevalent.
97-101
  
 
Ocular motor abnormalities, particularly saccadic abnormalities, are also a common 
feature of HD and have been noted for a number of years.
102-104
 Saccades are rapid eye 
movements that shift gaze from one location to another. The UHDRS includes a 
qualitative evaluation of saccade initiation and velocity wherein the neurologist scores 
performance on a five-point scale. Studies have shown that individuals with HD require 
blinks or head movements to facilitate saccade initiation,
105-109
 while normal individuals 
do not require any facilitation. However, Becker et al.
110
 suggested that facilitating 
movements are not required until the very late stages of severe HD. Since the UHDRS 
five-point scale relies heavily on the observance of head movements or blinks when 
initiating saccades, this evaluation is likely to be useful only during the late stages of the 
disease. Velocity is also evaluated as part of the UHDRS, but efficacy of this measure is 
also questionable. Many studies have shown that individuals with manifest HD have 
slower saccades,
105;108;110-116
 though the effect is associated with age such that impairment 
in saccade velocity is most pronounced at younger ages.
104;110;117
  While two studies using 
qualitative assessment of saccade velocity found differences in premanifest subjects,
98;118
 
subsequent studies using quantitative measures have not found saccadic slowing in either 
premanifest or manifest HD.
119
 
 
Despite the shortcomings of saccadic testing in the UHDRS, quantitative saccades have 
proven to be quite beneficial in detecting abnormalities even during the premanifest 
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period of HD. Furthermore, the development of portable saccadometry devices
120
 now 
provides a reasonable means for quantitatively measuring saccades in a clinical setting. 
Studies using quantitative saccades have reported increased latency of initiation
111;119;121-
126
 and variability of latency
111;119;122;124
 of voluntary saccades, and difficulty inhibiting 
saccades toward a novel visual stimulus
119;122;123;127
 in both premanifest and manifest HD. 
These results indicate that measures of latency, variability of latency, and correct 
responses during voluntary saccade tasks are promising biomarkers during the 
premanifest period of the disease. However, no studies have described the longitudinal 
progression of these measures in premanifest HD. 
 
2. Cognitive abnormalities in Huntington disease 
 
Cognitive deficits are a considerable source of morbidity in HD, progressively worsen 
during the course of the disease,
86
 and are more strongly associated with functional 
ability than motor symptoms.
128
 The term subcortical dementia has been used to describe 
the cognitive effects of the disease, but its use has been argued against
129
 in part because 
the symptoms often do not meet DSM-IV criteria for dementia until very late in the 
disease in spite of clear cognitive difficulty during earlier stages.
99;100;130-132
  A 
Physician’s Guide to the Management of Huntington’s Disease2 suggests heightened 
alertness for the following complaints: disorganization, lack of initiation, perseveration, 
impulsivity, irritability and temper outbursts, perceptual problems, unawareness, altered 
attention, language difficulties, learning and memory problems, and difficulty estimating 
time.  
 
A vast array of neuropsychiatric instruments has been used to study cognitive loss in HD, 
though some cognitive domains have been consistently identified as affected. For 
example, CAG+ individuals do not employ effective decision-making strategies in a 
simulated gambling task
133
 or a twenty questions game.
129
 One possible explanation is 
that they are unable to appropriately modify their behavior in response to the 
understanding gained from previous responses.
129;134
  Similarly, CAG+ individuals have 
difficulty with tasks that require shifting attention from a learned preparatory set to a new 
9 
 
set.
135
  Memory and learning problems are among the most common complaints of 
patients and family members.
129
 Based on studies that distinguish between different 
facets of memory, it appears that encoding and retrieval are impaired while recognition 
remains relatively intact.
136-138
 Another important cognitive impairment in HD is related 
to egocentric spatial judgment,
139-141
 which can negatively impact a person’s ability to 
read maps, maintain a sense of direction, and vary motor actions in response to spatial 
alterations. Dysfunctional language can severely impact the ability to communicate in 
HD. Though a major contributor to dysfunction is related to the motor impairments of the 
disease, non-motor impairments such as reduced fluency, decreased ability to switch 
between semantic categories, and lack of comprehension of complex sentences and 
implied information are also evident.
142-146
 
 
3. Behavioral abnormalities in Huntington disease 
 
Behavioral changes are quite common in HD, but unlike cognitive decline, behavior does 
not generally correlate with other measures of disease progression.
147
  Perhaps the most 
extensively studied psychiatric disorder in HD is depression. While some studies have 
found an increased risk of depression in CAG+ individuals (reviewed by Slaughter et 
al.
148
), an extensive recent study found that the lifetime prevalence of depression is not 
increased in CAG+ individuals compared to CAG- individuals who have a parent with 
HD, although the cross sectional prevalence of depression is increased.
149
  Suicidal 
ideation is common and fluctuates throughout the disease process, with highest 
prevalence in premanifest and late stage disease.
129
  Successful suicide is believed to be 
5-10 times higher in CAG+ individuals than in the general population.
150-153
 
 
Irritability is another common feature of HD.
151;154-156
 The prevalence has been shown to 
be increased up to 10 years prior to estimated disease onset,
149
 though no association 
between irritability and years to onset was found. Other behavioral manifestations include 
apathy,
151;157-159
 anxiety,
157;159-162
 and psychosis.
157;161;163-166
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D. Magnetic resonance imaging in Huntington disease 
 
Magnetic resonance imaging (MRI) has provided the ability to study the 
neurodegenerative effects of HD in vivo. Structural MRI analysis of gray matter has been 
used the longest, and specific patterns of disease have been consistently observed. 
Bilateral striatal atrophy has been identified in 95% of HD brains
167
 and is caused in part 
by the preferential loss of medium spiny neurons.
168;169
 Loss begins in the caudal dorsal 
medial caudate and progresses rostrally, ventrally, and laterally to eventually involve the 
caudate head, putamen, and globus pallidus.
167;170
 Atrophy can be detected up to 20 years 
prior to estimated disease onset, and the rate of volume loss increases significantly within 
10 years prior to onset.
171
  Striatal atrophy is a good indication of disease severity
172-175
 
and is associated with declining total functional capacity,
176
 memory,
177-179
 executive 
function,
177;180
 and psychomotor speed.
177;179
  In part because of these findings, Kloppel 
et al.
181
 suggested that striatal volume could be used to stratify patients in clinical trials in 
order to create more homogeneous groups. 
 
In addition to striatal volume loss, it is also clear that atrophy can be detected throughout 
the brain.
101;170;171;174;175;182-196
 Rosas et al.
193
 reported that the most consistent regions of 
cortical thinning in manifest HD occurred in sensorimotor regions of the frontal lobe. 
Studies of premanifest HD suggest that atrophy begins in the posterior regions of the 
brain and progress anteriorly with advancing disease.
101;193;194
 While loss of volume and 
thickness has been most consistently described, there have been reports of increased gray 
matter volume,
192
 increased ACC thickness,
194
 and enlarged gyral crowns
191
 in 
premanifest HD, and increased frontal lobe volume in manifest HD.
184
 
 
A number of studies have investigated neural abnormalities in HD using functional 
MRI
197-208
 (fMRI), and these are summarized in Table 2 (modified from Bohanna et 
al.
170
). Findings from these reports include both hypo- and hyperactivation of many 
different regions, and direction of activity changes in CAG+ groups depends on the 
specific task. Unfortunately, though not unexpectedly, these studies do not point to 
abnormalities in one common circuit that lead to the observed cognitive deficits. Another 
11 
 
approach in fMRI studies has been to examine the functional connectivity between 
regions. Wolf et al.
209;210
 found reduced connectivity between the left lateral prefrontal 
cortex (PFC), parietal cortex, and putamen in premanifest HD, and Thiruvady et al.
211
 
found reduced connectivity between ACC and lateral PFC in manifest HD. These studies 
point to clear functional changes in the premanifest and manifest HD brain, and that 
activation differences may be detectable before either task performance decline or 
atrophy.
206
 
   
1
2
 
Table 2. Summary of fMRI studies in premanifest and manifest HD. 
Authors Task 
Task-activated  
regions 
Hypoactivation 
in CAG+ 
Hyperactivation  
in CAG+ 
Manifest HD 
    
Clark et al. 
(2002) 
Porteus maze Striatum 
Cerebellum 
Occipital cortex 
Temporal cortex 
Parietal cortex 
Frontal cortex 
Striatum 
Occipital cortex 
Parietal cortex 
Somato-motor cortex 
Frontal cortex 
     
Kim et al. 
(2004) 
Serial reaction 
time 
Striatum 
Thalamus 
Temporal cortex 
Frontal cortex 
Striatum 
Frontal cortex 
Occipital cortex 
None 
     
Georgiou-
Karistianis et 
al. (2007) 
Simon task Parietal cortex 
SMA 
Precentral gyrus 
Controls only: 
Putmen 
HD only: 
ACC 
Insula 
Premotor cortex 
Frontal cortex 
None ACC 
Insula 
IPL 
Superior temporal gyrus 
IFG 
Precuneus/SPL 
Precentral gyrus 
Dorsal premotor cortex 
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Table 2. Summary of fMRI studies in premanifest and manifest HD. 
Authors Task 
Task-activated  
regions 
Hypoactivation 
in CAG+ 
Hyperactivation  
in CAG+ 
     
Gavazzi et al. 
(2007) 
Repetitive finger 
flexion and 
extension 
Precentral gyrus 
Cerebellum 
Insula 
Caudate 
ACC 
Medial frontal gyrus 
Infraparietal sulcus 
Supramarginal gyrus 
SMA 
     
Wolf et al. 
(2009) 
Working 
memory 
Frontal cortex 
Parietal cortex 
Striatum 
Cerebellum 
HD only:  
Thalamus 
DLPFC 
VLPFC 
IPL 
Putamen 
Cerebellum 
None 
Premanifest HD 
    
Reading et al. 
(2004) 
Interference task PFC 
Cingulate cortex 
Parietal cortex 
Occipito-temporal cortex 
ACC None 
     
Paulsen et al. 
(2004) 
Time 
discrimination 
Striatum 
Pre-SMA/cingulate 
Caudate 
Thalamus 
ACC 
Pre-SMA 
     
Hennenlotter et 
al. (2004) 
Disgust 
processing 
Insula 
Putamen 
Insula 
Putamen 
None 
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Table 2. Summary of fMRI studies in premanifest and manifest HD. 
Authors Task 
Task-activated  
regions 
Hypoactivation 
in CAG+ 
Hyperactivation  
in CAG+ 
     
Wolf et al. 
(2007) 
Working 
memory 
Striatum 
Cerebellum 
Parietal cortex 
Frontal cortex 
Middle frontal gyrus IPL 
Superior frontal gyrus 
     
Zimbelman et 
al. (2007) 
Time 
reproduction 
Putamen 
Cerebellum 
ACC 
Frontal cortex 
Temporal cortex 
Far from onset: 
ACC 
Insula  
Close to onset: 
Putamen 
SMA 
Insula 
IFG 
Far from onset: 
Sensorimotor cortex 
Medial frontal gyrus 
Precentral gyrus 
Superior temporal gyrus 
Cerebellum 
     
Saft et al. 
(2008) 
Auditory 
processing and 
habituation 
 Close to onset: 
IPL 
ACC 
Middle frontal gyrus 
Insula 
Far from onset: 
Thalamus 
Caudate 
Manifest HD: 
Putamen 
     
Kloppel et al. 
(2009) 
Sequential finger 
movements 
Frontal cortex 
SPL 
None Caudal SMA 
SPL 
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E. Saccade signaling pathways in the brain 
 
There are several types of saccades that are used in a research setting (Figure 2). One of 
the simplest types is a prosaccade (PS), a type of visually-guided saccade that shifts gaze 
toward a visual stimulus. A PS is often termed reflexive, though the accuracy of the term 
has been questioned
212
 because cognitive processes clearly influence PS initiation. A 
volitional saccade is a second type of saccade. It is an endogenously generated gaze shift 
in response to a command. Antisaccades (AS), which require the suppression of a 
reflexive saccade toward a peripheral visual stimulus and the voluntary generation of a 
saccade to the mirror opposite location, and memory-guided saccades (MG), which 
require making a saccade to one or more remembered positions that are no longer 
Figure 2. Saccadic tasks and target locations. The dotted circle, not shown to 
participants, indicates the correct location of gaze. A. The AS task requires 
directing gaze away from the target. B. The MGs task requires fixation on the 
center target until it is extinguished, then directing gaze toward the remembered 
location of the peripheral target. C. The MGi task requires saccades toward the 
peripheral targets as they appear, then replication of the sequence to the 
remembered target locations. D. The MGc task requires fixation on the center target 
until it is extinguished, then sequentially directing gaze toward the remembered 
location of the 3 peripheral targets. 
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identified by a stimulus, are two types of volitional saccades that are particularly affected 
in premanifest and early manifest HD.
119;122;124
  
 
Saccades are generated via activity in the brainstem: oculomotor, trochlear, and abducens 
nuclei; medullary reticular formation; midbrain reticular formation; interstitial nucleus of 
Cajal; nucleus prepositus hypoglossi; paramedian pontine reticular formation; rostral 
interstitial nucleus of the medial longitudinal fasciculus; superior colliculus.
213
  However, 
many cortical regions influence the activity in these brainstem regions and thus control 
saccade behavior. Functional imaging in humans and single neuron recordings in non-
human primates have helped to identify these fairly well-defined cortical regions. 
 
PS generation is preceded or accompanied by activity in several cortical regions (Figure 
3), including visual cortex, parietal cortex, and frontal and supplementary eye fields 
(FEF, SEF) (reviewed in McDowell et al.
214
). The visual stimulus is sent to primary (V1) 
and secondary (V2/V3, middle occipital gyrus) visual cortex where its location is mapped 
in visual space. Contrary to all other regions, visual cortex may activate more strongly 
when making PS than when making volitional saccades.
215
 Visual cortex then projects 
directly to the superior colliculus
216;217
 and to the parietal cortex via the dorsal stream.
218
  
Widespread and varied activation has been noted throughout the parietal cortex,
215;219-222
 
but the most consistently activated regions are located in the superior parietal lobule 
(SPL). The parietal cortex is important for visuo-spatial processes.
223-226
  The parietal 
cortex has direct projections to the superior colliculus
227;228
 and is reciprocally connected 
with regions in the frontal lobe,
229;230
 particularly the FEF and SEF. FEF are located in 
Brodmann area 6, immediately anterior to the motor strip
231;232
 and are important in 
generating saccades.
233;234
  SEF are located on the dorsomedial surface of the frontal lobe, 
just anterior to the supplementary motor area
235;236
 (SMA). While activated during PS, 
SEF appear to be more important for tasks involving remembered ocular motor sequences 
or predictable stimuli.
237-242
 Both FEF and SEF project to the brainstem saccade 
generators,
243-246
 and direct stimulus of either region is sufficient to produce a saccade.
247-
249
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Volitional saccades activate the same regions as PS, though typically to a greater degree 
(with the previously noted exception of the visual cortex). Parietal cortex plays a number 
of important roles in AS performance. The inferior parietal lobule (IPL) appears to inhibit 
saccades toward the peripheral stimulus,
250
 while an area along the intraparietal sulcus 
(IPS) is responsible for vector inversion
219;251-254
 (remapping the location of the stimulus 
to its mirror opposite location). FEF activity is detected prior to the initiation of an AS, 
suggesting an increase of preparatory inhibition
255;256
 and prospective saccadic coding.
257
 
Similar to FEF, SEF activation is detected prior to saccade initiation. Evidence suggests 
that SEF activation may slow the PS response, thereby allowing the AS to be initiated 
first.
258-260
  
 
As with AS tasks, MG tasks elicit activation similar to PS though to a greater degree. In a 
simple version of the task (MGs, Figure 2B), the parietal cortex, and IPS in particular, is 
activated during the delay period after the stimulus but prior to the response,
261
 consistent 
Figure 3. Schematic of cortical saccade pathways. The cerebral cortex exerts top-
down control on the brainstem saccade generators. Visual cortex, parietal cortex, 
frontal cortex, and cingulate cortex have all been shown to activate during saccadic 
tasks. ACC = anterior cingulate cortex; DLPFC = dorsolateral prefrontal cortex; FEF 
= frontal eye fields; SEF = supplementary eye fields. 
 
 
 18 
 
with its role in visuo-spatial attention. FEF activation is also persistent during the delay 
period and may represent maintenance of the location of the cue.
257;261-266
 
 
In a more complex MG task (MGc, Figure 2D), both the location and sequence of the 
visual stimuli must be remembered. Given the role supplementary motor areas in motor 
sequence learning,
267-269
 it is not surprising that SEF plays a prominent role in the 
planning, learning, and execution of MGc tasks.
220;270
  IPS is also activated under these 
conditions and may represent an online visuo-spatial recoding of the stimulus locations in 
order to account for new eye position after making a saccade to a previous target.
220;271-273
  
Greater activation compared to PS is also found in FEF,
274;275
 supporting its important 
role in volitional saccade generation. 
 
In addition to activating regions that overlap with PS, volitional saccades also activate 
dorsolateral prefrontal cortex
214;221;222;250;255;276-278
 (DLPFC) and anterior cingulate cortex 
(ACC). These regions play an important role in both saccadic and non-saccadic cognitive 
control: DLPFC is involved in attention, planning, spatial orientation, and 
inhibition;
279;280
 and ACC is involved in conflict and error monitoring.
280-282
 
 
During an AS task, DLPFC activation precedes the saccadic response prior to correct 
trials,
255;277;283;284
 and lesions in DLPFC lead to more AS errors, but do not affect 
PS.
233;285;286
 In MG tasks, DLPFC appears to play a role in inhibition
266;276;283;287
 and 
maintenance of spatial orientation.
263;288-291
  Relevant to saccadic control, DLPFC sends 
projections to FEF
292
 and superior colliculus.
293;294
 
 
ACC is activated during both AS and MG tasks. Prior to saccadic response in an AS task, 
ACC activity is associated with subsequent correct responses,
283
 consistent with its role 
in conflict monitoring; however, post-response ACC activation is associated with 
incorrect responses,
283;295
 consistent with an error monitoring role. This error monitoring 
role appears to be the major contribution of ACC during MG tasks.
220
 While connectivity 
in the context of saccades has not been studied in ACC, regions of the ACC activated by 
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saccadic tasks are connected with parietal cortex, motor and pre-motor cortex, and dorsal 
prefrontal cortex.
296
 
 
F. Biomarkers of Huntington disease 
 
Unfortunately, there are no current pharmacologic or therapeutic interventions shown to 
delay or slow the onset or progression of HD. Therefore, it is essential that sensitive and 
specific biomarkers in the prediagnostic period be identified that could be used to 
evaluate future therapeutic interventions. Biomarkers are objective measurements that are 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to therapeutic interventions.
297
 They must be sensitive and 
specific for the process or response being evaluated, and they must also show reliability, 
validity, responsiveness, precision, interpretability, acceptability, and feasibility.
298
 It has 
been shown that the proposed saccadic measurements are good candidates for HD 
biomarkers.
119;122
 We have recently shown that saccadic measures satisfy biomarker 
criteria such as high between-session reliability, strong genetic influence, and limited 
abnormalities in a CAG+ population.
299
 
 
Several studies have sought to identify potential prediagnostic biomarkers, and it is well-
established in cross sectional studies that prediagnostic CAG+ individuals experience 
deficits in tests of attention,
300
 executive function,
99;301;302
 memory,
131;300;301;303;304
 
psychomotor speed,
98;99;118;131;300;305
 and ocular movements.
98;99;111;119;120;122;306
  However, 
biomarkers must be characterized longitudinally in order to be effective measures of 
therapeutic intervention. In a large cross sectional sample of 438 prediagnostic 
individuals, Paulsen and colleagues
100
 reported that the detectable changes begin one to 
two decades prior to the estimated age of onset, and that this initial period is followed by 
more rapid change in the years just prior to diagnosis. While this study was very well-
powered (a weakness of many prediagnostic biomarker studies), care must be taken when 
making longitudinal interpretations of cross sectional data because cross sectional studies 
cannot control for effects of learning, training, etc.  
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Only a few longitudinal studies have explored rates of decline in prediagnostic CAG+ 
individuals. Some have reported differential rates of progression between premanifest 
CAG+ and CAG- controls in measures of attention, psychomotor speed, and 
memory;
130;307-310
 however, others have not been able to replicate these results.
311-314
 
These discrepant results may be due to the modest sample sizes of most studies and to the 
challenge presented by the extensive heterogeneity of the disease phenotype.  
 
G. Statement of Purpose 
 
HD is, in many ways, ideally suited for studying neurodegenerative disease; its 
Mendelian inheritance is relatively straightforward, a simple gene test can 
unambiguously predict future onset of the disease, and its late onset allows for a thorough 
study of the prodromal phase. Studying the disease is not, however, without challenges. 
The ubiquitous expression of huntingtin protein belies the focal neural pathology, and the 
variable symptomology greatly complicates research intended to characterize the defining 
characteristics of premanifest disease. The goal of these studies was to gain a better 
understanding of the mechanisms of saccadic impairment in HD and of the potential for 
using saccades to follow premanifest HD. This was accomplished through the following 
aims: 
 
1. Identify the neural correlates of saccade impairment in premanifest and manifest HD. 
 
A. Using structural MRI and a focused region of interest (ROI) approach, identify 
specific regions of brain atrophy associated with saccade impairment. 
 
B. Using fMRI, determine the functional brain changes that underlie AS 
impairment. 
 
2. Determine the pattern of progression of neuropsychological and ocular motor decline 
within the premanifest period of HD. 
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A. Identify measures for which the rate of decline increases as premanifest 
individuals approach onset. 
 
B. Identify measures for which the rate of decline is faster in CAG+ than CAG- 
individuals. 
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II. Vertical antisaccade latency tracks gray matter atrophy in premanifest and early 
manifest Huntington disease 
 
A. Introduction 
 
Huntington disease (HD) is an autosomal dominant disorder caused by an expanded 
number of CAG repeats in the huntingtin gene.
1
 The diagnosis of HD is currently based 
on the Unified Huntington Disease Rating Scale (UHDRS), although abnormalities can 
be detected before a clinical diagnosis of HD becomes certain (i.e. during the premanifest 
period of the disease). These abnormalities are potential biomarkers that offer insights 
into premanifest disease progression, and indicate the brain systems that are first to be 
affected.  
 
Quantitative measurements of saccadic eye movements are one such potential set of 
biomarkers of disease progression. A saccade is a rapid eye movement that shifts gaze 
from one location to another. An extensive and systematic study of manifest HD
107
 found 
that the most profound changes were in the ability to initiate voluntary saccades and to 
maintain fixation.  Subsequent studies in premanifest and manifest HD have found 
abnormalities in  antisaccade (AS) and memory guided (MG) measures of latency, 
variability of latency, and error rates.
98;99;104;111;119-124;306
  There is also evidence that the 
rate of impairment increases in some MG tasks for measures of the variability of latency 
and error rate.
315
  Interestingly, despite early evidence that abnormalities of vertical 
saccades were possibly more prominent than those of horizontal saccades,
107
 recent 
studies have focused on horizontal saccades. 
 
Striatal atrophy is a well-known and long-established sign of HD progression
170;187
 and 
can be detected using structural MRI up to 10 years prior to disease onset.
101;171
  
However, atrophy is not limited to the striatum, and has also been detected in the 
thalamus and multiple cortical regions.
101;174;175;182-186;188-192;195;196;316
 It has been 
suggested that cortical atrophy begins in posterior regions and progresses 
anteriorly.
101;193;194
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The association between gray matter changes and saccade performance in HD has not 
been described. This study examines the relationship between regional loss of cerebral 
gray matter and saccadic parameters that differentiate between CAG- and CAG+ groups. 
By understanding these relationships, clinically assessable markers can be derived that 
are closely associated with the loss of both striatal and cortical tissue in the premanifest 
period. 
 
B. Methods 
 
1. Participants 
 
Participants were recruited primarily from individuals who had taken part in previous 
studies at Indiana University. The inclusion criteria were: 1) a parent diagnosed with HD; 
2) age between 18 and 65; 3) no diagnosis of HD, or if diagnosed, having received the 
diagnosis within the past 2 years. 121 participants completed the saccade protocol, and a 
subset of 31 participants was also imaged. All those who were imaged self-reported right 
handedness. No participants reported a concurrent neurologic illness, major psychiatric 
diagnosis (e.g. schizophrenia, bipolar disorder), or current alcohol or drug abuse. 
Participants were asked not to disclose their CAG status, if known, to study staff. This 
study was approved by the local institutional review board (IUPUI IRB Study Nos. 0109 
and 0707) and all participants provided written informed consent. 
 
2. Clinical Evaluation and Study Group Assignment 
 
Molecular testing was used to determine the number of CAG repeats in the huntingtin 
gene.
317
 Participants with 2 alleles having fewer than 28 repeats were considered CAG 
unexpanded (CAG-; n=47; 12 in imaging subset), while those having at least 1 allele with 
more than 38 CAG repeats were considered CAG expanded (CAG+; n=74; 19 in imaging 
subset). 
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An experienced movement disorder neurologist (J.W., X.B.) administered the motor 
portion of the Unified Huntington Disease Rating Scale-99
87
 (UHDRS). The neurologists 
were aware that the participants were at-risk for HD, but were blinded to the results of all 
other study assessments, including huntingtin gene testing. On the basis of the motor 
examination only, the neurologist assigned an overall confidence rating (UHDRS 
diagnosis confidence level) that represented the likelihood of motor abnormalities 
attributable to HD. The ratings are defined as: (0) normal (no abnormalities); (1) 
nonspecific motor abnormalities (less than 50% confidence); (2) motor abnormalities that 
may be signs of HD (50% to 89% confidence); (3) motor abnormalities that are likely 
signs of HD (90% to 98% confidence); and (4) motor abnormalities that are unequivocal 
signs of HD (≥ 99% confidence). Those CAG+ subjects with a confidence rating from 0-
3 were considered premanifest (preHD; n=49; 12 in imaging subset), while those 
receiving a 4 were considered to have manifest HD (HD; n=25; 7 in imaging subset). 
Estimated onset was defined as the age at which a person had a 50% probability of 
having manifest disease, and the estimated time to onset (TTO) was calculated for each 
preHD participant.
84;100
 PreHD subjects were further classified as far from estimated 
onset (Far; TTO>13 years; n=25) and near to estimated onset (Near; TTO<13 years; 
n=24). Because of the small sample, dichotomization of the preHD group was not used in 
the imaging data analysis. 
 
3. Eye Movement Recording and Analysis 
 
Participants were seated in front of a 22 inch computer LCD monitor in a standard 
ophthalmology exam chair. Visual targets (3 mm red spot) were displayed on a monitor 
placed 23.5 inches from the participant. As part of the pre-testing procedure, calibration 
and validation were completed. Four saccadic tasks were administered (Figure 2): AS; 
MG, simple (MGs); MG, intermediate (MGi); and MG, complex (MGc). The vertical and 
horizontal positions of the participants’ pupils were recorded binocularly with two ultra-
miniature high-speed (250 Hz) video cameras attached to a headband. Four sensors 
monitored head movements; eye positions were adjusted for small head movements 
(EyelinkII, SR Research Ltd, spatial resolution < 0.1 degree). Before each task, the 
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examiner instructed the participant verbally and then provided a brief view of the task to 
ensure that the participant understood the instructions. Each of the tasks consisted of 24 
trials. After the participant completed the testing procedure, an interactive computerized 
analysis of the right eye position was performed.  
 
Measures of latency, variability of latency, and percentage of errors
119;122
 (including 
missed flashes for MGc) were tested for group differences (CAG-, Far, Near, HD) using 
analysis of covariance (ANCOVA) in SAS v9.13. A significant ANCOVA test (p≤0.05) 
was followed by one-tailed t-tests between CAG- and Far groups, Far and Near groups, 
and Near and HD groups. Age, gender, and education were included in the model as 
covariates when they had a significant effect (p≤0.05). A linear trend analysis was also 
performed with Far, Near, and HD groups to test for evidence of linear decline in CAG+ 
subjects, suggesting progressive impairment in the premanifest and early manifest stages 
of disease. Those measures with a significant linear trend (p≤0.05) were used in the 
correlation analysis with structural measures. 
 
4. Image Acquisition and Analysis 
 
A subset of participants (31 total: 12 CAG-, 12 preHD, 7 HD) were imaged in a Siemens 
(Erlangen, Germany) 3T Magnetom Trio-Tim scanner with a 12-channel head-coil array. 
A whole-brain, high resolution (1.0 × 1.0 × 1.2 mm voxels) structural image volume was 
acquired using a 3D magnetization prepared rapid gradient echo (MPRAGE) sequence.  
 
An automated parcellation and segmentation procedure in FreeSurfer V4
318-321
 was used 
to extract cortical thickness and volume measures. Analyses focused on FreeSurfer 
segmented and parcellated structures that overlap with regions known to mediate saccade 
function: dorsolateral prefrontal cortex (DLPFC) in rostral middle frontal gyrus (rMFG), 
frontal eye fields (FEF) in caudal MFG (cMFG), supplementary eye fields (SEF) in 
superior frontal gyrus (SFG), inferior parietal lobule (IPL), and the caudate 
nucleus.
104;214;253;262;322-327
  The rostral and caudal anterior cingulate cortex (rACC, 
cACC) were also included because of their monitoring role in volitional 
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saccades.
214;220;221;295;322;328-331
  ANCOVA was used to test for group differences (CAG-, 
preHD, HD) in thickness and volume. A significant ANCOVA test (p≤0.05) was 
followed by two-tailed t-tests for all groupwise comparisons. Age, gender, and 
intracranial volume (ICV) were included in the model as covariates, when they had a 
significant effect (p≤0.05).  
 
5. Structural-Saccadic Relationships 
 
Due to the modest size of the imaged sample, a Spearman nonparametric correlation 
model was used to test for an association between saccade impairment and brain atrophy 
in saccade-related regions. Only saccadic measures with a significant linear trend (see 
above) and structural regions with a significant group difference were used. This assured 
that the saccadic measures used are those that show progression, and that the 
relationships between cortical volume and saccadic measures occur in regions where 
cerebral degeneration can be measured. Gender, age, and ICV were included in the model 
as partial variables. 
 
C. Results 
 
In the large primary sample, the 4 study groups (CAG-, Far, Near, HD) did not 
significantly differ in education, gender, race, or handedness (p≥0.6; Table 3), although 
the Far group was significantly younger than the other three groups (p≤0.0005). In the 
subset of participants that underwent imaging, there were no significant group (CAG-, 
preHD, HD) differences (p≥0.1).  
  
 
2
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Table 3. Participant demographics. Data for imaged participants are listed in parentheses. 
 
    
PreHD 
   
 
CAG- Far Imaged Subset Near HD 
Number of 
Participants 
47 
(12) 
25 
 
 
(12) 
24 
 
25 
(7) 
Age* (years) 47.1 
(46.1 
± 
± 
11.2 
11.4) 
36.0 
 
± 
 
11.1 
 
 
(43.9 
 
± 
 
14.4) 
47.6 
 
± 
 
11.7 
 
48.9 
(45.5 
± 
± 
11.7 
15.0) 
Education 
(years) 
15.2 
(14.8 
± 
± 
2.3 
2.1) 
15.3 
 
± 
 
2.3 
 
 
(16.6 
 
± 
 
4.1) 
16.1 
 
± 
 
3.2 
 
15.3 
(14.0 
± 
± 
2.6 
1.5) 
Male:Female 12:35 
(5:7) 
8:17 
 
 
(5:7) 
10:14 
 
8:17 
(2:5) 
Race  
(% Caucasian) 
100 
(100) 
100 
 
 
(100) 
100 
 
100 
(100) 
Handedness  
(% right) 
89.4 
(100) 
88.0 
 
 
(100) 
87.5 
 
88.0 
(100) 
CAG Repeats in 
Larger Allele 
19.9 
(20.2 
± 
± 
3.0 
3.3) 
42.4 
 
± 
 
2.5 
 
 
(42.5 
 
± 
 
2.2) 
42.9 
 
± 
 
2.9 
 
43.7 
(45.4 
± 
± 
4.0 
5.5) 
Estimated Time 
to Onset (years)    
18.1 
 
± 
 
3.4 
 
 
(13.1 
 
± 
 
6.4) 
9.0 
 
± 
 
2.1 
    
* The Far group was significantly younger than all other groups for the larger non-imaging sample (p≤0.0005) 
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1. Saccade Abnormalities and Linear Decline 
 
There was a significant difference (p≤0.05) in the performance of the Far and Near 
groups (Table 4) for: AS) percentage of horizontal errors, and latency of correct 
horizontal and vertical AS; MGs) percentage of horizontal errors; and MGc) percentage 
of errors. Additionally, there was a significant difference between the Near and HD 
groups for the measures: AS) percentage of horizontal and vertical errors; MGs) 
variability of latency of correct vertical saccades; MGi) percentage of errors; MGc) 
percentage of errors and missed flashes. There were no saccadic measures for which a 
significant difference between the CAG- and Far groups was detected. 
 
A significant linear decline (p≤0.05) across CAG+ groups (Far, Near, HD) was found for 
the measures (Table 4): AS) percentage of horizontal and vertical errors, and horizontal 
and vertical latency; MGs) latency of horizontal saccades; MGi) percentage of errors; 
MGc) percentage of errors and missed flashes.  
 
2. Atrophic Brain Changes 
 
There was a significant group (CAG-, preHD, HD) effect on thickness and volume for 
many cortical and subcortical regions (Table 5), consistent with previous studies. There 
was a significant loss of thickness in preHD compared with CAG- subjects in the frontal 
lobe (bilateral SFG, left rMFG and cMFG) and parietal lobe (bilateral IPL). There was 
also a loss of volume bilaterally in the caudate. When comparing the HD with preHD 
subjects, there was a loss of thickness in the parietal lobe (right IPL) and of volume 
bilaterally in the caudate. There was a significant difference between CAG- and HD for 
all above mentioned regions. There was no significant loss of thickness in the rACC or 
cACC. 
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Table 4. Group differences in saccade performance. 
 
  Unadjusted Mean ± SD   
Antisaccades 
 
CAG-  Far  Near  HD 
Group 
Differences  
(p value) 
Linear 
Trend in 
CAG+  
(p value) 
% Errors 
Hrz 20.3 ± 18.9 
 
16.3 ± 22.4 
 
29.4 ± 22.8 
 
43.8 ± 28.5 
b (0.02), c 
(0.02) 
0.0004 
Vrt 30.6 ± 19.3  25.8 ± 23.0  32.2 ± 25.5  52.3 ± 29.2 c (0.002) 0.002 
Latency 
(ms) 
Hrz 288.9 ± 47.7  283.4 ± 49.9  309.5 ± 44.8  321.0 ± 54.6 b (0.02) 0.05 
Vrt 304.6 ± 47.2  300.2 ± 51.2  344.3 ± 75.5  371.8 ± 56.1 b (0.005) 0.03 
Variability 
of Latency 
(ms) 
Hrz 50.5 ± 23.8  60.0 ± 32.5  62.1 ± 28.5  73.6 ± 74.0 * * 
Vrt 55.4 ± 25.7  73.1 ± 48.8  73.1 ± 58.5  99.1 ± 75.6 † * 
Memory Guided Saccades (simple)           
% Errors 
Hrz 24.8 ± 15.0  25.5 ± 20.6  38.0 ± 24.8  39.8 ± 23.4 b (0.01) * 
Vrt 17.6 ± 17.3  27.5 ± 16.0  29.4 ± 20.7  33.7 ± 25.7 * * 
Latency 
(ms) 
Hrz 299.9 ± 64.1  309.7 ± 60.8  326.5 ± 59.4  357.9 ± 82.0 † 0.02 
Vrt 319.2 ± 68.0  306.3 ± 63.3  339.5 ± 67.3  374.3 ± 105.3 † * 
Variability 
of Latency 
(ms) 
Hrz 82.6 ± 40.6  104.1 ± 59.1  106.9 ± 47.8  111.5 ± 50.3 * * 
Vrt 94.8 ± 46.6  91.9 ± 67.3  110.1 ± 55.3  150.4 ± 70.8 c (0.004) * 
a - CAG- vs. Far; b - Far vs. Near; c - Near vs. HD; * - non-significant test; † - significant ANCOVA with no significant post hoc 
tests. Significance of p≤0.05 used for all tests. Hrz- horizontal, Vrt - vertical. 
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Table 4. Group differences in saccade performance. 
 Unadjusted Mean ± SD   
 
CAG-  Far  Near  HD 
Group 
Differences  
(p value) 
Linear 
Trend in 
CAG+  
(p value) 
Memory Guided Saccades (intermediate)             
% Errors  14.8 ± 14.9  24.5 ± 21.0  32.9 ± 28.7  55.8 ± 29.0 c (0.0004) 0.0004 
Latency 
(ms) 
 359.9 ± 88.0 
 
362.3 ± 113.9 
 
363.3 ± 121.5 
 
340.4 ± 97.3 * * 
Variability of 
Latency (ms) 
151.4 ± 48.5 
 
147.9 ± 41.3 
 
151.4 ± 78.5 
 
151.0 ± 95.8 * * 
Memory Guided Saccades (complex)            
% Errors  18.3 ± 14.0 
 
24.2 ± 20.2 
 
43.7 ± 25.7 
 
66.7 ± 29.0 
b (0.0007), c 
(0.0003) 
<0.0001 
% Missed Flashes 7.9 ± 10.9  11.4 ± 15.7  14.2 ± 18.8  28.8 ± 28.3 c (0.003) 0.01 
a - CAG- vs. Far; b - Far vs. Near; c - Near vs. HD; * - non-significant test; † - significant ANCOVA with no significant post hoc 
tests. Significance of p≤0.05 used for all tests. Hrz- horizontal, Vrt - vertical. 
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Table 5. Gray matter atrophy in saccade-related brain regions.  
  Unadjusted Mean ± SD  
Frontal Lobe  CAG- Prediagnostic CAG+ Manifest HD Post hoc 
Superior Frontal Gyrus 
Left
1
 2.62 ± 0.14 2.51 ± 0.13 2.48 ± 0.06 a, b 
Right
1
 2.54 ± 0.12 2.44 ± 0.11 2.43 ± 0.07 a, b 
Rostral Middle Frontal Gyrus 
Left
1,2
 2.34 ± 0.12 2.23 ± 0.09 2.20 ± 0.11 a, b 
Right
1
 2.19 ± 0.11 2.16 ± 0.11 2.13 ± 0.03  
Caudal Middle Frontal Gyrus 
Left
1
 2.49 ± 0.10 2.39 ± 0.11 2.32 ± 0.08 a, b 
Right
1
 2.44 ± 0.10 2.42 ± 0.12 2.35 ± 0.04  
Parietal Lobe      
Inferior Parietal Lobule 
Left
1
 2.43 ± 0.11 2.29 ± 0.12 2.20 ± 0.13 a, b 
Right
1
 2.48 ± 0.12 2.38 ± 0.16 2.27 ± 0.16 a, b, c 
Cingulate Cortex      
Rostral Anterior Cingulate  
Left 2.70 ± 0.23 2.76 ± 0.23 2.66 ± 0.21  
Right
1
 2.69 ± 0.17 2.61 ± 0.20 2.67 ± 0.14  
Caudal Anterior Cingulate  
Left
2,3
 2.61 ± 0.29 2.71 ± 0.29 2.53 ± 0.14  
Right 2.41 ± 0.23 2.42 ± 0.22 2.37 ± 0.30  
Subcortical            
Caudate nucleus 
Left
1,2,3
 3436.7 ± 400.1 3078.7 ± 282.6 2268.4 ± 447.6 a, b, c 
Right
1,2,3
 3522.8 ± 439.2 3151.0 ± 354.5 2411.0 ± 341.5 a, b, c 
 
Cortical structural measure is gray matter thickness in mm while subcortical measure for the caudate nucleus  is volume in mm^3. 
Post hoc testing indicates a significant difference (p≤0.05) between a) CAG- and preHD, b) CAG- and HD, and c) preHD and HD. 
Superscripts indicate significant effects (p≤0.05) of covariates: 1) age, 2) gender, 3) ICV. 
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Table 6. Correlation coefficients (p values) of significant associations between measures 
of brain atrophy and saccade impairment.  
  AS MGi MGc 
Frontal Lobe  
% Errors 
(vertical) 
Latency 
(vertical) % Errors % Errors 
% Missed 
Flashes 
SFG Left 
0.53 
(0.04) 
-0.62 
(0.05) 
   
Parietal Lobe       
IPL Left  
-0.74 
(0.01) 
   
Subcortical 
      
Caudate 
nucleus 
Left  
-0.88 
(0.0008) 
-0.49 
(0.05) 
-0.58 
(0.02) 
-0.66 
(0.005) 
Right  
-0.91 
(0.0003) 
  
-0.62 
(0.01) 
 
AS: antisaccade; IPL: inferior parietal lobule; MGc: memory guided, complex; MGi: memory 
guided, intermediate; SFG: superior frontal gyrus. 
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Figure 4. Plots of vertical AS latency and structural measures. Filled circles represent 
CAG+ individuals, and unfilled triangles represent CAG-. Plots are of vertical AS latency 
vs. left SFG thickness (A) and right caudate volume (B). 
 
A. 
 
 
B. 
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3. Structural-Saccadic Relationships in CAG+ Individuals 
 
A significant negative association (Table 6) was found between vertical AS latency and 
thickness in the left SFG (Figure 4A) and left IPL and bilateral caudate volume (p≤0.05, 
Figure 4B). The percentage of errors of MGi and MGc were negatively associated with 
left caudate volume, and the percentage of missed flashes (MGc) was negatively 
associated with bilateral caudate volume. The percentage of vertical AS errors was 
positively associated with left SFC thickness. There were a number of saccadic and 
structural measures tested that had no significant associations: percentage of horizontal 
AS errors, horizontal AS and MGs latency, right SFG and IPL, and left rMFG and 
cMFG. 
 
D. Discussion 
 
This study is the first to describe the gray matter correlates of saccade impairment in HD. 
We found that horizontal and vertical eye movements dissociated Far, Near, and HD 
groups. On the basis of saccade measures alone, it was not clear that either horizontal or 
vertical movements were better suited for studying the disease. However, only vertical 
AS latency was related to both cortical and subcortical gray matter loss in several areas, 
suggesting that vertical AS are more informative of disease-related atrophy than either 
horizontal AS or MG measures. 
 
1. Eye movement findings 
 
Our results confirm findings from previous studies that AS latency and error rate are 
affected in preHD.
119;122;124
  Horizontal and vertical latency are slowed in the premanifest 
period (Far vs. Near). While we did not find a significant difference between the Near 
and HD groups, we did find a significant linear trend across the 3 CAG+ groups. This 
could be explained by a ceiling effect wherein latency does not continue to slow 
indefinitely in individuals with manifest disease. We also found group differences in the 
percentage of AS errors in both directions. The significant increases were found between 
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the Near and HD groups in both horizontal and vertical directions, and between Far and 
Near in horizontal AS only. This demonstrates that the AS task is quite useful for 
measuring premanifest disease progression, and that both latency and percentage of errors 
are informative. 
 
The results from the MG tasks suggest that the more challenging MGi and MGc tasks are 
more sensitive than MGs in measuring decline during the premanifest period. There was 
significant impairment in the HD group in the percentage of errors (MGi and MGc) and 
the percentage of missed flashes (MGc). Furthermore, the Near group made more errors 
than the Far group during the MGc task. The linear trend among CAG+ groups was 
significant for all three measures. The percentage of correct saccades in the MGc task 
appears more sensitive than other MG measures in detecting a gradual progression in 
premanifest and early manifest HD, although the very low percentage of correct 
responses in manifest HD (33.3%) suggests that a ceiling effect may be reached when 
studying progression beyond the earliest stages of manifest disease. It is also important to 
note that none of the measures were able to detect differences between the CAG- and Far 
from onset groups. This may be explained in part by the observation that the Far group 
was significantly younger than the CAG- group. 
 
Association Between Atrophy and Saccade Impairment 
 
The neural correlates of these saccade impairments are largely unknown in HD. In 
healthy individuals FEF and SEF are activated to a greater extent during volitional 
saccades than during reflexive saccades.
214
  These regions send projections to the 
superior colliculus directly and via the caudate.
104;332
  Reflexive saccades are thought to 
be triggered in the parietal lobe via direct projections to the superior 
colliculus,
104;227;228;333
 though there is considerable evidence that the parietal lobe plays an 
important role in AS and MG saccades as well.
219-221;250-254;257;261-264
  Importantly, the 
frontal and parietal lobes are interconnected so that an absolute distinction between their 
functions is unlikely.
104;229
  The one study examining neural correlates of saccades in HD 
used diffusion tensor imaging to examine the relationship between white matter integrity 
  
36 
 
and voluntary saccades.
334
  They found that the variability of voluntary saccade latency 
increased as the percentage of fibers connecting the FEF and the caudate decreased, 
suggesting that fiber loss in this important connection in the saccadic pathway could be 
the source of increased variability of latency in preHD. 
 
In this study we examined the gray matter correlates of saccade function. We limited our 
analysis to regions of interest in saccade function, including FEF, SEF, IPL, DLPFC, and 
caudate (see Methods). The most striking associations between cerebral degeneration and 
saccadic measures were with the latency of vertical AS. This was the only saccadic 
measure that was sensitive to both cortical and subcortical atrophy, and it explained more 
of the variation in size in left SFG, left IPL, and bilateral caudate than any of the other 
saccadic measures. Subsequent analysis of the associations between the structural 
measures (left SFG, left IPL, bilateral caudate) indicated that this finding is not entirely 
explained by correlation between the structural measures; left IPL thickness was 
significantly associated with the other structures (p≤0.01), but left SFG thickness was not 
associated with caudate volume (p≥0.2). On the other hand, MG task performance is only 
affected by subcortical atrophy. The caudate is a major site of cortical input to the basal 
ganglia,
335;336
 and appears to play a role in both the initiation
337
 and inhibition
338
 of 
saccades. This is consistent with its role as a relay between the cortex and ocular motor 
output.
104
  Our findings suggest that increased vertical AS latency is related to changes in 
the caudate, SEF, and IPL, and that vertical AS latency may be one of the more sensitive 
markers of cortical and subcortical volume loss in premanifest and early manifest HD. 
  
One major strength of this study was that all imaging and saccadic data were collected at 
the same study visit, thus avoiding any time-dependent discrepancies between the 
saccadic and structural measures. Also, all participants in the study had a parent 
diagnosed with HD which increased the degree of matching between the groups for 
environmental and other non-measurable influences. On the other hand, this study was 
limited by the relatively small number of individuals who were imaged. This precluded 
whole brain analysis of the neural correlates of saccade function and reduced our power 
to detect significant associations. We are also limited in our ability to conclude that there 
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are no group differences in saccades between CAG- and individuals far from onset due to 
the age differences between these groups. 
 
This study is the first to describe the gray matter correlates of saccade impairment in HD. 
The results suggest that cortical and subcortical atrophy contribute to slowed vertical AS 
responses, while MG performance is only influenced by subcortical volume loss. While 
there were few behavioral differences between vertical and horizontal AS, the strong 
associations between gray matter loss and vertical AS latency suggest that future studies 
would be well-served to measure vertical AS, which may be an early clinical indication 
of disease manifestation. 
  
  
38 
 
III. Abnormal error-related antisaccade activation in premanifest and early 
manifest Huntington disease 
 
A. Introduction 
 
Huntington disease (HD) is an autosomal dominant disorder caused by an expanded 
number of CAG repeats (CAG+) in the huntingtin gene.
1
 The disease is characterized by 
progressive worsening of motor, cognitive, and behavioral control. Diagnosis is based on 
the Unified Huntington Disease Rating Scale
87
 (UHDRS), which emphasizes motor 
abnormalities. However, many studies indicate that cognitive,
99;131;300-303
 psychomotor, 
98;99;118;131;300;305
 and psychiatric signs
154;157;339-344
 can be detected during the premanifest 
(presymptomatic) period, before a diagnosis of HD is certain.  
 
Abnormalities in saccades, rapid eye movements that shift gaze from one location to 
another, are widely observed in HD.
98;99;104;111;119-124;306
 However, a distinction between 
types of saccades is important. A prosaccade (PS) is a type of visually-guided saccade 
that shifts gaze toward a visual stimulus. A PS is often termed reflexive, though the 
accuracy of the term has been questioned
212
 because cognitive processes clearly influence 
PS initiation. On the other hand, a volitional saccade is an endogenously generated 
movement in response to a command. It is these volitional saccades that are particularly 
affected in premanifest and early HD.
111;119;120;122
 An antisaccade (AS) is a type of 
volitional saccade that requires the suppression of a reflexive saccade toward a peripheral 
visual stimulus, and the voluntary generation of a saccade to the mirror opposite location 
of the stimulus. As compared to those who do not have the disease-causing expansion 
(CAG-), both premanifest and manifest HD subjects make more AS errors and have 
longer and more variable latencies of AS initiation.
119;122;124
  
 
PS are generated by activity in known brain regions, including the visual cortex, parietal 
cortex, frontal and supplementary eye fields (FEF, SEF), striatum, and superior colliculus 
(reviewed recently by McDowell and colleagues
214
). Given that AS require a conscious 
executive component, their successful execution depends on multiple processes such as 
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planning, reflex suppression, and error monitoring. Based on functional magnetic 
resonance imaging (fMRI) studies, AS generation activates the same regions as does PS 
generation, albeit to a greater extent,
214
 with the possible exception of the visual 
cortex.
215;277
 In addition to regions activated by PS, AS also activate dorsolateral 
prefrontal cortex
214;221;222;250;255;276-278
 (DLPFC) and anterior cingulate 
cortex
221;295;322;328;331;345
 (ACC). Lesions in the DLPFC lead to more AS errors, but do not 
affect PS.
233;285;286
  The ACC plays a role in conflict monitoring generally,
280-282
 and 
increased activity in the period preceding an AS is associated with better performance.
283
 
On the other hand, increased ACC activity is associated with errant reflexive saccades 
during the response phase of an AS task,
283;295
 suggesting an error monitoring role for the 
ACC as well. 
 
Separating the preparatory period leading to an AS (i.e. knowing the instruction to make 
an AS while awaiting the cue to execute it) and the response period (i.e. the presentation 
of the peripheral stimulus and the saccadic response) is one strategy to help disentangle 
planning and error. Using such an approach, Brown et al.
324
 identified the FEF, SEF, 
DLPFC, ACC, and intraparietal sulcus (IPS) as active during AS preparation, while FEF, 
SEF, and IPS regions were involved in the response period. Others have similarly 
identified the pre-supplementary motor area (pre-SMA), FEF, and SEF as important 
regions in maintaining the preparatory set necessary for correct AS performance.
258;346
 
 
A number of studies have investigated neural abnormalities in HD using fMRI .
197;199-
206;208-211;347
 Findings from these reports include both hypo- and hyperactivation of many 
different regions. However, the neural abnormalities underlying impaired AS in HD have 
not been investigated. We used an event-related AS paradigm to investigate whether 
performance of an AS task in a sample of individuals at-risk for HD (at least one parent 
with diagnosed HD) was affected by: 1) abnormal brain activity while preparing for an 
AS response, or 2) abnormal activity while executing an AS.  
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B. Methods 
 
1. Participants 
 
Participants were recruited primarily from individuals who had taken part in previous 
studies. The inclusion criteria were: 1) parent diagnosed with HD; 2) age between 18 and 
65; 3) no diagnosis of HD, or if diagnosed, having received the diagnosis within the past 
2 years; and 4) self-reported right-handedness. No participants reported a concurrent 
neurologic illness, major psychiatric diagnosis (e.g. schizophrenia, bipolar disorder), or 
current alcohol or drug abuse at any visit. Participants were asked not to disclose their 
CAG status, if known, to study staff. This study was approved by the local institutional 
review board (IUPUI IRB Study No. 0109). All participants provided written informed 
consent. 
 
2. Clinical Evaluation and Study Group Assignment 
 
Molecular testing of the huntingtin gene was performed
317
 to determine the number of 
CAG repeats. Individuals in the CAG unexpanded (CAG-) group had 2 alleles with fewer 
than 28 CAG repeats (n=12). Individuals with at least 1 allele of more than 38 CAG 
repeats were considered CAG expanded (CAG+; n=19). One CAG+ participant was not 
included in the analysis due to excessive motion during imaging, resulting in a final 
sample size of 18 CAG+ individuals. 
 
An experienced movement disorder neurologist (J.W.) administered the motor portion of 
the UHDRS.
87
 The neurologist was aware that the participants were at-risk for HD, but 
was blind to the results of all other study assessments, including huntingtin gene testing. 
On the basis of the motor examination only, the neurologist assigned an overall 
confidence rating (UHDRS diagnosis confidence level) that represented the likelihood of 
motor abnormalities attributable to HD. The ratings were defined as: (0) normal (no 
abnormalities); (1) nonspecific motor abnormalities (less than 50% confidence); (2) 
motor abnormalities that may be signs of HD (50% to 89% confidence); (3) motor 
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abnormalities that are likely signs of HD (90% to 98% confidence); and (4) motor 
abnormalities that are unequivocal signs of HD (≥ 99% confidence). Those CAG+ 
participants with a confidence rating from 0-2 were considered premanifest (preHD, 
n=10), while those receiving a 3 or 4 were considered to have manifest HD (n=8). 
 
Neuropsychological performance was evaluated using measures from four tests: 1) 
Wechsler Adult Intelligence Scale-Revised
348
 (WAIS-R): Digit Symbol subtest; 2) 
Symbol Digit Modalities Test 
349
 (SDMT); 3) Stroop Color-Word Interference Task:
350
  
Word Reading, Color Naming, Interference; and 4) H-scan system:
351
 Movement Time 
(MT) and Alternate Button Tapping. Analysis of covariance (ANCOVA) was used to test 
for group differences, with age, gender, and education included as covariates. Covariates 
were removed from the model when not significant to preserve statistical power. 
 
3. Antisaccade Paradigm 
 
A mixed event-related design was used to study brain activation elicited by PS and AS 
(Figure 5). Similar to Brown et al.,
322
 participants were initially given a color-coded 
instruction to perform a PS or an AS (Figure 5, panel 1). The instruction was then 
extinguished with the simultaneous appearance of a peripheral stimulus. Subjects were 
instructed to look at the stimulus (PS trials) or in the mirror-opposite location of the 
stimulus (AS trials; Figure 5, panel 2). The peripheral stimulus was then extinguished and 
a centrally-located white circle appeared, upon which participants fixated their gaze while 
awaiting the next instruction (Figure 5, panel 3). Sixteen PS and sixteen AS trials were 
presented in each 5:20 minute functional imaging scan in a pseudorandom order using E-
prime (www.pstnet.com/eprime.cfm). All but two participants completed four functional 
imaging scans; one terminated the protocol after the third scan due to loss of sensation in 
his arms, and eye movement data were not collected during one scan for another. 
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4. Eye Movement Recording and Analysis 
 
An R-LRO 6.1 eye-tracking system designed for fMRI (Applied Science Laboratories, 
Bedford, MA) was used to track eye movements during imaging at a sampling rate 
frequency of 60 Hz. Eye movements were analyzed offline using a semi-automated, in-
house software program written in Matlab (http://www.mathworks.com) as described 
previously.
122
 For each trial, the saccade was determined to be either correct or incorrect. 
We also identified self-corrected AS errors, defined as an initial saccade made toward the 
stimulus that was corrected by making a saccade away from the stimulus. No external 
feedback was given to the participants regarding accuracy. The percentages of incorrect 
trials and of self-corrected AS errors were then determined, and ANCOVA was used to 
test for between-group differences (CAG-, preHD, manifest HD) with age, gender, and 
Figure 5. The fMRI task protocol. A central circle turns green (G) for a PS (A) 
and red (R) for an AS (B) (panel 1). The circle is extinguished as a horizontal 
peripheral square (stimulus) appears. For a PS, participants look at the square; for an 
AS, participants look directly opposite the square (panel 2). The central circle then 
reappears (panel 3), upon which participants fixate while awaiting the next 
instruction. Repetition time = 2000 ms. Dotted circle = correct eye position (shown 
here for illustration purposes, but not visible to participants during testing). 
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education included as covariates when appropriate. A significant ANCOVA (p ≤ 0.05) 
was followed by one-tailed t-tests of all pairwise comparisons.  
 
5. Image Acquisition and Analysis 
 
Subjects were imaged using a Siemens (Erlangen, Germany) 3T Magnetom Trio-Tim 
scanner with a 12-channel head-coil. A whole-brain, structural image volume (1.0 × 1.0 × 
1.2 mm voxels) was acquired first using a 3D magnetization prepared rapid gradient echo 
(MPRAGE) sequence to enable anatomic registration of the functional volumes.
352
 
Functional imaging was performed with a blood oxygenation level dependent (BOLD) 
contrast sensitive gradient echo, echo-planar imaging sequence (repetition time 2000 ms, 
echo time 29 ms, flip angle 76˚, field of view 220 × 220 mm, 35 interleaved axial slices, 
2.5 × 2.5 × 3.0 mm voxels) incorporating a 3D prospective acquisition correction 
algorithm, which adjusts the acquisition in real time to account for head movement. 
 
Given that atrophy in the caudate and putamen have been consistently 
described,
173;178;182;183;186;192;353;354
 an automated segmentation procedure in FreeSurfer 
V4
321
 was used to extract caudate and putamen volumes from each individual’s structural 
image. We then used ANCOVA with age, gender, and intracranial volume (ICV) as 
covariates to test for group differences. Post hoc analysis was carried out on all measures 
with a significant group effect using a two-tailed t-test for all pairwise comparisons. 
 
Image analysis was performed using SPM5 (Wellcome Trust Centre for Neuroimaging, 
University College London, UK, http://www.fil.ion.ucl.ac.uk/spm/). Functional image 
volumes were corrected for slice acquisition timing differences and rigid-body realigned 
to the initial volume of the first functional imaging scan, which was also a reference 
volume for MPRAGE co-registration. The MPRAGE volume segmentation into tissue 
classes generated nonlinear spatial transformation parameters enabling a conversion of 
functional image volumes to a common coordinate system (Montreal Neurological 
Institute; MNI). The resulting functional image volumes were resampled to 2 mm 
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isotropic voxels and smoothed by a 6 mm full-width at half-maximum isotropic Gaussian 
kernel.
355
  
 
Brain responses to eye movements in each participant were modeled in a general linear 
model using SPM’s canonical hemodynamic response function. Six movement 
parameters (three translations and three rotations) obtained during realignment were 
included as regressors to account for residual movement-induced effects. Serial 
correlations in the fMRI time series were accounted for using an autoregressive model 
implementing classical (restricted maximum likelihood) parameter estimation. A high-
pass filter with a cut-off of 1/128 Hz was applied to each voxel’s time series to remove 
low frequency noise.  
 
A first level model yielded contrast images for each participant that represented the mean 
BOLD response to three eye movement conditions:  [correct AS > correct PS], [correct 
AS > incorrect AS], [incorrect AS > correct AS]. Incorrect AS trials included both self-
corrected and uncorrected AS errors. BOLD activity associated with PS error trials was 
not modeled due to the very small number of errors made by all participants on the PS 
trials. Event onsets were defined for: 1) the preparation phase, which included the times 
of the instructional stimulus presentations; and 2) the response phase, which included the 
times of the peripheral stimulus presentations. This second approach was feasible since 
all participant reaction times were less than 750 msec. A second level, random effects 
analysis within the CAG- group was then used to identify activated regions that achieved 
a corrected cluster level significance (pcluster<0.05) under a voxel-wise height threshold of 
pvoxel<0.001. The correction for multiple comparisons was performed within a whole-
brain search volume common across all CAG- participants, with implicit rejection of 
cerebrospinal fluid voxels and exclusion of predominantly white matter voxels 
(probability of white matter from SPM segmentation>0.70). Functional regions of 
interest (ROI) were defined for each significant cluster in the CAG- group under each eye 
movement condition described above. These ROIs were then used as the criterion to 
define ―normal‖ activation in an unaffected, healthy sample. Mean activity within each 
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ROI was extracted in all participants using the MarsBaR toolbox 
(http://marsbar.sourceforge.net/).  
 
To compare the mean activation among the groups, it is important to account for the 
frequency of incorrect responses.
295
 Thus, a multiple linear regression model 
implemented in SAS version 9.13 was used to examine the relationship between mean 
activation and group, percentage of incorrect AS, and the interaction between group and 
percentage of incorrect AS. The preHD group was treated as the reference group in the 
model so that comparisons could be made between the CAG- and preHD groups and 
between the preHD and manifest HD groups. Age, gender, and education were included 
as covariates in the model when they had a significant effect on the model (p≤0.05). 
 
C. Results 
 
The demographics, neuropsychological test performance, and caudate and putamen 
volumes of the sample are shown in Table 7. The groups did not differ significantly in 
age, education, or gender, and there was no significant difference in the number of CAG 
repeats in the larger allele for the two CAG+ groups. There was a significant difference 
(p≤0.03) between the groups in measures of psychomotor speed (movement time and 
alternate button tapping). Post hoc testing revealed a difference between the CAG- and 
manifest HD groups (p=0.005) for movement time and between the manifest HD group 
and both the CAG- and preHD groups (p≤0.01) for alternate button tapping. As expected, 
and consistent with previous studies,
173;178;182;183;186;192;353;354
 the groups also differed in 
caudate and putamen volumes bilaterally, and all three pairwise group comparisons were 
highly significant (p≤0.001). 
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Table 7. Participant demographics. 
 
CAG-  
(n=12) 
PreHD 
(n=10) 
Manifest  
HD (n=8) 
Age (years) 46.4 ± 11.4 44.2 ± 15.2 42.8 ± 13.4 
Education (years) 14.8 ± 2.1 15.7 ± 3.2 15.8 ± 4.4 
Gender (M:F)  5:7 4:6 3:5 
# of CAG repeats in 
larger allele 
20.2 ± 3.3 42.2 ± 2.1 45.5 ± 5.1 
Movement Time (s)
b
 0.14 ± 0.03 0.16 ± 0.05 0.19 ± 0.05 
Alternate Button 
Tapping (s/30 round 
trips)
b,c
 
17.3 ± 3.0 18.1 ± 3.0 21.9 ± 4.1 
Stroop Color Naming 
(correct/45 s) 
76.9 ± 16.7 85.3 ± 10.3 70.5 ± 14.6 
Stroop Word Reading 
(correct/45 s) 
97.0 ± 23.9 103.9 ± 15.4 94.5 ± 14.2 
Stroop Interference 
(correct/45 s) 
47.2 ± 10.7 48.9 ± 9.2 43 ± 8.9 
Symbol Digit Modalities 
Test (correct/90 s) 
54.2 ± 8.8 48.8 ± 13.3 41.8 ± 9.0 
WAIS-R Digit Symbol 
(correct/90 s) 
59.0 ± 14.9 60.4 ± 10.3 50.0 ± 14.9 
Caudate 
(mm
3
) 
Left
a,b,c
 3437 ± 400 3151 ± 251 2384 ± 463 
Right
a,b,c
 3523 ± 439 3215 ± 343 2541 ± 368 
Putamen 
(mm
3
) 
Left
a,b,c
 5448 ± 885 4925 ± 785 3644 ± 720 
Right
a,b,c
 5116 ± 701 4679 ± 893 3359 ± 616 
 
Post hoc testing indicates a significant difference (p≤0.05) between a) CAG- and preHD, 
b) CAG- and manifest HD, and c) preHD and manifest HD. 
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1. Antisaccade task performance 
 
ANCOVA was used to test for group differences in the percentages of incorrect PS and 
AS. A significant group effect was found for both the percentages of incorrect PS and AS 
(p≤0.02) (Figure 6). For the PS task, post hoc testing revealed that the CAG- group made 
significantly fewer errors than both CAG+ groups (p≤0.01), although the error rates were 
low overall. For the AS task, the manifest HD group made significantly more errors than 
the CAG- and preHD 
groups (p≤0.05), and 
there was a trend toward 
a difference between the 
CAG- and preHD 
groups (p=0.08). More 
than 85% of AS errors 
were self-corrected in all 
groups, with no 
statistical difference 
between the groups 
(p=0.6). 
 
2. BOLD responses during AS task (Table 8, Figure 7). 
 
a. Preparation, [correct AS > correct PS]. Eleven functional ROIs emerged as significant 
within the CAG- group (Figure 7A): Left and right DLPFC; left and right FEF; right 
anterior insula/frontal operculum; pre-SMA/dorsal ACC (dACC); left and right parietal 
eye field (PEF); left and right middle occipital gyrus; and right calcarine cortex.  
 
When testing extracted mean activations in a multiple linear regression model, there was 
a significant main effect of group and an interaction between group and percentage of 
incorrect AS in the left middle occipital gyrus (p=0.03). Further testing revealed a 
significant difference between the slopes and intercepts of the regression lines in the 
Figure 6. Performance on the PS and AS tasks. For the 
PS task, the CAG- group made significantly fewer errors 
than the preHD and manifest HD group. For the AS task, 
the manifest HD group made significantly more errors than 
the CAG- and preHD groups. 
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preHD and manifest HD groups (Table 8, Figure 8A). There was also a significant effect 
of the percentage of incorrect AS in the left DLPFC (Figure 8B), pre-SMA/dACC, left 
and right PEF, and left middle occipital gyrus (p≤0.03). In all cases, the BOLD response 
decreased as the percentage of incorrect AS responses increased.  
 
b. Response, [correct AS > correct PS]. One functional ROI emerged as significant within 
the CAG- group in the right PEF (Figure 7B). There were no significant effects of group, 
percentage of incorrect AS, or their interaction in this ROI (p≥0.3, Table 8). 
 
c. Preparation and response, [correct AS > incorrect AS]. No functional ROIs were 
defined as there were no regions that met our criteria in the CAG- group during either 
preparation or response. 
 
d. Preparation, [incorrect AS > correct AS]. Two functional ROIs were significant within 
CAG- group (Figure 7C): Left and right calcarine cortices. ANCOVA revealed a 
significant effect of group in the left calcarine cortex (p=0.03). Post hoc testing showed a 
significant difference between the CAG- and preHD groups (p = 0.02, Table 8). 
 
e. Response, [incorrect AS > correct AS]. Six functional ROIs emerged as significant 
within the CAG- group (Figure 7D): 1) Left inferior frontal gyrus (IFG); 2) pre-SMA; 3) 
dACC; 4) posterior cingulate cortex (PCC); 5) right inferior parietal lobule (IPL); and 6) 
left middle temporal gyrus (MTG). 
 
A significant interaction between group and percentage of incorrect AS (p≤0.03) was 
found for all functional ROIs except the PCC, with the same general pattern across these 
ROIs (Table 8). In all cases the slope of the regression line was significantly different 
between the CAG- and preHD groups (p≤0.02), but not significantly different between 
the preHD and manifest HD groups (p≥0.3). Specifically, the BOLD response decreased 
as the percentage of incorrect AS increased in the CAG- group, but not in either of the 
CAG+ groups (Figures 8C: pre-SMA, and 4D: dACC). 
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Table 8. ROI locations and sizes as defined by CAG- controls, and non-zero linear regression parameter estimates and p values 
(with preHD as the reference group) from the modeling of ROI-extracted mean activations. 
 
 Contrast/ROI  Parameter Estimates (p values) 
     Group  Percentage of 
Incorrect AS 
 Group x Percentage 
of Incorrect AS 
 
Size 
(mm
3
) 
 
Peak MNI 
Location 
(x,y,z) 
 
PreHD vs 
CAG- 
 
PreHD vs 
Manifest 
HD 
 
 
 
[PreHD vs 
CAG-] x 
Percentage of 
Incorrect AS 
 [PreHD vs 
Manifest HD] 
x Percentage 
of Incorrect 
AS 
Correct AS > Correct 
PS 
             
Preparation              
Left DLPFC 464  -30, 44, 34      -0.02 (0.02)     
Right DLPFC 1480  28, 44, 22           
Left FEF 3184  -18, 0, 66           
Right FEF 3696  18, 4, 62           
Right Anterior 
Insula/Frontal 
Operculum 
640  38, 20, 4           
Pre-SMA/dACC 6776  -4, 10, 50      -0.03 (0.01)     
Covariates that remained in the model due to a significant effect (p<0.05) are indicated by superscripts: * education, † age. dACC: dorsal 
anterior cingulate cortex; DLPFC: dorsolateral prefrontal cortex; FEF: frontal eye field; IPL: inferior parietal lobule; MTG: middle 
temporal gyrus; PCC: posterior cingulate cortex; PEF: parietal eye field; pre-SMA: pre-supplementary motor area. 
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Table 8. ROI locations and sizes as defined by CAG- controls, and non-zero linear regression parameter estimates and p values 
(with preHD as the reference group) from the modeling of ROI-extracted mean activations. 
 
 Contrast/ROI  Parameter Estimates (p values) 
     Group  Percentage of 
Incorrect AS 
 Group x Percentage 
of Incorrect AS 
 
Size 
(mm
3
) 
 
Peak MNI 
Location 
(x,y,z) 
 
PreHD vs 
CAG- 
 
PreHD vs 
Manifest 
HD 
 
 
 
[PreHD vs 
CAG-] x 
Percentage of 
Incorrect AS 
 [PreHD vs 
Manifest HD] 
x Percentage 
of Incorrect 
AS 
Left PEF* 1584  -20, -58, 52      -0.03 (0.001)     
Right PEF* 4384  18, -66, 52      -0.04 (0.0008)     
Left Middle 
Occipital Gyrus*
†
 
 
480  -26, -80, 20    -1.66 
(0.02) 
 -0.05 (0.0004)    0.05 (0.01) 
Right Middle 
Occipital Gyrus 
1024  30, -80, 20           
Right Calcarine 
Gyrus 
1240  12, -80, 6           
Stimulus-response              
Right PEF 1136  8, -60, 54           
Covariates that remained in the model due to a significant effect (p<0.05) are indicated by superscripts: * education, † age. dACC: dorsal 
anterior cingulate cortex; DLPFC: dorsolateral prefrontal cortex; FEF: frontal eye field; IPL: inferior parietal lobule; MTG: middle 
temporal gyrus; PCC: posterior cingulate cortex; PEF: parietal eye field; pre-SMA: pre-supplementary motor area. 
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Table 8. ROI locations and sizes as defined by CAG- controls, and non-zero linear regression parameter estimates and p values 
(with preHD as the reference group) from the modeling of ROI-extracted mean activations. 
 
 Contrast/ROI  Parameter Estimates (p values) 
     Group  Percentage of 
Incorrect AS 
 Group x Percentage 
of Incorrect AS 
 
Size 
(mm
3
) 
 
Peak MNI 
Location 
(x,y,z) 
 
PreHD vs 
CAG- 
 
PreHD vs 
Manifest 
HD 
 
 
 
[PreHD vs 
CAG-] x 
Percentage of 
Incorrect AS 
 [PreHD vs 
Manifest HD] 
x Percentage 
of Incorrect 
AS 
Incorrect AS > 
Correct AS 
Preparation              
Left Calcarine 
Gyrus 
2912  -14, -54, 8  2.54 
(0.02) 
        
Right Calcarine 
Gyrus 
1304  20, -54, 14           
Stimulus-response              
Left Inferior 
Frontal Gyrus 
632  -42, 20, -18  5.40 
(0.001) 
     -0.15 (0.01)   
Pre-SMA 1704  16, 16, 58  4.93 
(0.0001) 
     -0.13 (0.003)   
Covariates that remained in the model due to a significant effect (p<0.05) are indicated by superscripts: * education, † age. dACC: dorsal 
anterior cingulate cortex; DLPFC: dorsolateral prefrontal cortex; FEF: frontal eye field; IPL: inferior parietal lobule; MTG: middle 
temporal gyrus; PCC: posterior cingulate cortex; PEF: parietal eye field; pre-SMA: pre-supplementary motor area. 
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Table 8. ROI locations and sizes as defined by CAG- controls, and non-zero linear regression parameter estimates and p values 
(with preHD as the reference group) from the modeling of ROI-extracted mean activations. 
 
 Contrast/ROI  Parameter Estimates (p values) 
     Group  Percentage of 
Incorrect AS 
 Group x Percentage 
of Incorrect AS 
 
Size 
(mm
3
) 
 
Peak MNI 
Location 
(x,y,z) 
 
PreHD vs 
CAG- 
 
PreHD vs 
Manifest 
HD 
 
 
 
[PreHD vs 
CAG-] x 
Percentage of 
Incorrect AS 
 [PreHD vs 
Manifest HD] 
x Percentage 
of Incorrect 
AS 
dACC 1224  0, 16, 24  6.20 
(0.0002) 
     -0.18 (0.003)   
PCC 664  2, -14, 36  4.53 
(0.002) 
        
Right IPL 456  50, -42, 38  2.68 
(0.0007) 
     -0.07 (0.02)   
Left MTG 720  -60, -34, -4  4.56 
(<0.0001) 
     -0.11 (0.001)   
Covariates that remained in the model due to a significant effect (p<0.05) are indicated by superscripts: * education, † age. dACC: 
dorsal anterior cingulate cortex; DLPFC: dorsolateral prefrontal cortex; FEF: frontal eye field; IPL: inferior parietal lobule; MTG: 
middle temporal gyrus; PCC: posterior cingulate cortex; PEF: parietal eye field; pre-SMA: pre-supplementary motor area. 
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Figure 7. Functional ROIs defined in CAG- participants for each saccade comparison. (A) Significant activation during 
preparation for the [correct AS > correct PS] comparison in the bilateral DLPFC, FEF, PEF, and middle occipital gyri; the right insula 
and calcarine cortex; and the pre-SMA/dACC. (B) Significant response-related activation for [correct AS > correct PS] in the right 
PEF. (C) Significant activation during preparation for the [incorrect AS > correct AS] comparison in the bilateral calcarine cortices. 
(D) Significant activation during responses for [incorrect AS > correct AS] in the left IFG, pre-SMA, dACC, PCC, right IPL, and left 
MTG. AS = antisaccade; dACC = dorsal anterior cingulate cortex; DLPFC = dorsolateral prefrontal cortex; FEF = frontal eye fields; 
IFG = inferior frontal gyrus; IPL = inferior parietal lobule; L = left; MTG = middle temporal gyrus; PCC = posterior cingulate cortex; 
PEF = parietal eye fields; pre-SMA = pre-supplementary motor area. 
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Figure 8. BOLD response [incorrect AS > correct AS] as a function of the percentage of incorrect AS. In the left middle 
occipital gyrus (MOG) (A), activation is dependent on the percentage of incorrect AS in the CAG- and preHD groups but not in the 
manifest HD group, and the manifest HD group has lower overall activation. In the left DLPFC (B), activation decreases as the 
percentage of incorrect AS increases in all 3 groups. In the pre-SMA (C) and dACC (D) activation is dependent on the percentage of 
incorrect AS in the CAG- group but not in either CAG+ group; the CAG- group has greater overall activation. Furthermore, there are 
no differences in activation between the preHD and manifest HD groups. dACC = dorsal anterior cingulate cortex; DLPFC = 
dorsolateral prefrontal cortex; pre-SMA = pre-supplementary motor area. 
A. 
 
 
B. 
 
C. 
 
 
D. 
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D. Discussion 
 
1. Identified brain regions 
 
This is the first study to explore the BOLD fMRI response during an AS task in CAG+ 
individuals. The brain regions activated by AS (with a baseline of PS) within the CAG- 
group closely resemble those from previous studies of other populations
322-324
 (Figure 
7A). In particular, our healthy control CAG- participants activated the DLPFC, FEF, 
PEF, insula, ACC, pre-SMA. The increased activation in the visual cortex was consistent 
with some studies,
255
 though other studies have found the opposite pattern.
215;277
 During 
the response phase, activation was limited to the right PEF.  
  
Activation related to AS errors (with a baseline of correct AS) was limited to visual 
cortex during preparation, but was more widespread during the response phase as 
evidenced by activation in the IFG, pre-SMA, ACC, PCC, IPL, and MTG. Previous 
studies have typically identified the ACC as being activated by errant saccades,
283;295
 and 
Polli et al.
295
 also found increased activation in the IFG, pre-SMA, and anterior insula. 
Similar error-monitoring activity in the ACC and in a more dorsal pre-SMA area has 
been described in non-saccadic tasks as well,
281;356-363
 suggesting that these areas are 
critical to the monitoring of errant behavior more generally. 
 
2. Abnormal Activation in CAG+ Groups 
 
Abnormalities in AS performance are sensitive markers of the premanifest period of 
HD.
110;119;364
 Given these previous findings, it would be reasonable to hypothesize that 
activation abnormalities would be found either in the preparation or response phase of an 
AS task (compared to a PS baseline). Our analysis found some group differences in the 
left middle occipital gyrus while subjects prepared to make AS, but further examination 
makes this finding of questionable significance: In particular, although the regression line 
was significantly less negative in the manifest HD, no one in this group had an AS error 
rate of less than 20%. Since the BOLD response was dependent on the percentage of 
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incorrect AS in the other 2 groups, it is possible that the differences in this group can be 
explained solely by the restriction of range. Instead, the cortical activity that did 
distinguish between these groups was related to AS errors in the response phase (with a 
baseline of correctly executed AS). Specifically, activity was inversely related to the 
percentage of incorrect AS in the CAG- controls, but not in the preHD or manifest HD 
patients. In the case of the preHD, restriction of range cannot explain this difference, as 
the distribution of error rates was similar across both the preHD and the CAG- groups. 
 
Activity in the ACC and pre-SMA (two of the five areas in which group × error 
interaction emerged) is likely to be particularly important. Both of these regions are 
repeatedly noted as sites of error-related activation, even in studies that do not involve 
ocular motor responses.
281;356-363
 Furthermore, an event related potential (ERP) study of 
error processing showed decreased error-related negativity (ERN) during a Flanker task 
in patients with manifest HD.
365
  That is, brain responses to provoked behavioral errors 
were less prominent in HD subjects than in healthy controls—a result that mirrors our 
findings with AS errors.  
 
Detection of errant behavior, or of events that violate expectations, is a necessary 
function for executive control, and the failure to process such errors will lead to poor 
adaptive behavior. The dopaminergic mesocorticolimbic brain circuit has received much 
attention for its hypothesized roles in reward related processing.
366;367
  However, a key 
element in this processing is the learned anticipation of outcomes based on experience, 
and the detection of events that do not conform to these learned expectations. For 
example, seminal work by Schultz and his collaborators has shown that dopaminergic 
midbrain neurons increase their firing to unanticipated events, and decrease their firing 
when an anticipated (cued) reward fails to arrive.
368;369
  Holroyd and Coles
370
 elaborate 
on such findings and hypothesize that medial frontal (ACC, pre-SMA) areas are signaled 
by this midbrain activity, provoking their engagement in error (deviant event) processing. 
Moreover, midbrain dopaminergic neurons are smaller and have a loss of tyrosine 
hydroxylase mRNA in HD.
371
  Thus, one potential explanation of our findings is an early 
loss of midbrain signaling in preHD patients. 
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Although both the ACC and pre-SMA are consistently implicated in error-related 
activation, there are also questions about the exact nature of each region’s role in 
saccadic pathways. Compelling evidence from a rare patient with a small focal lesion to 
the left supplementary eye field (SEF), posterior to the pre-SMA,
240;372
 suggests SEF 
involvement in resolving conflict both from internally generated saccadic plans and 
during rule switching, but not in saccade generation per se. Similarly, functional imaging 
data show that activity in caudal SMA is related to sudden changes in planned saccades, 
while SEF activity is related to successfully implemented plan changes.
373
 In primates, 
Schall et al.
374
 localized different populations of neurons in the ACC, pre-SMA, and 
adjacent SEF, wherein one population of neurons accounted for conflict-related 
activation, one for reinforcement-related activation, and one for error-related activation; 
thus, one region may play a role in multiple functions.  
 
The ACC also has connections to important regions in saccadic pathways. In a meta-
analysis of cingulate cortex, Beckmann et al.
296
 characterized a cluster in the dACC (their 
―cluster 4‖) that overlaps with the region activated in our study by AS error trials, and 
which appears to mediate conflict resolution and error detection. Through tractography, 
Beckmann et al.
296
 showed this dACC region has white matter projections to prefrontal 
and premotor areas, as well as to the dorsal striatal regions that are an early site of 
degeneration in HD. Picard and Strick
375
 similarly identified an overlapping rostral 
cingulate motor zone in their meta-analysis as governing conflict and action selection.  
 
Reinforcing our findings in HD, other disorders with presumed frontal and dopaminergic 
involvement also show functional brain abnormalities linked to errors in AS. In 
particular, similar error-related activation in the ACC was significantly reduced in a 
sample of schizophrenic patients
376
 at peak coordinates [8, 13, 25]/[-13, 17, 25] that were 
quite close to our own [0, 16, 24]. Conversely, Thakkar et al.
377
 reported that in autism 
spectrum disorders there is dACC hyperactivation in response to correct AS, which was 
in turn related to rigid and repetitive behavior. 
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While pre-SMA and cingulate cortex have received the most attention for their roles in 
error-related activation, there is evidence that the IPL and IFG have related roles. A 
number of studies identify the IPL as playing an important role in the inhibition of an 
unwanted response,
281;322;357;360
 while others have found that the IPL is activated in 
response to error commission.
358;361;363
 Interestingly, most of these studies
322;357;360;363
 
found evidence for asymmetric activation of the right IPL. Findings in the IFG have been 
reported even more rarely than in the IPL, but Hodgson et al.
378
 showed that lesions in 
ventrolateral frontal cortex (including IFG) predict impaired AS performance. There is 
also evidence of error-related activation in the IFG.
295;362
 These previous findings and the 
similarity of the activation patterns between the IPL and IFG and the pre-SMA and 
dACC suggest that these regions may play a role in the error-related network along with 
pre-SMA and cingulate cortex, although more study is necessary.  
 
This study was limited by the inability to dichotomize the preHD group into groups 
estimated to be closer to or farther from onset. Similarly, we were unable to use estimated 
time to onset
84
 in our analysis because of the limited number of participants in the preHD 
group. As we focused our group analysis on those regions with significant activation in 
the CAG- healthy control group, we cannot make conclusions regarding the recruitment 
of other brain regions in an attempt to compensate for pathology in regions normally 
involved in task performance. However, our method did permit detecting deviant 
activation in CAG+ individuals in regions usually involved in task performance (though 
only decreased activation was found). Unlike prior studies, and contrary to expectations, 
there was only a marginal difference in the percentage of incorrect AS between the CAG- 
and preHD groups (p = 0.08). However, it is likely that a smaller sample size and 
adaptation of the task to a more difficult mixed event-related design contributed to this 
finding.  
 
In summary, this is the first study to examine the underlying functional neuroanatomy 
associated with AS performance in HD. While future studies, including longitudinal ones, 
are necessary to determine the temporal appearance of abnormalities within the context of 
disease progression, our data suggest that impaired AS performance may be related to 
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abnormal cortical activity during the processing of saccadic errors. Importantly, deficits 
in this error-related activity appear to occur early in the disease process (i.e., in 
premanifest individuals with normal AS performance), pointing to a prodromal decline in 
an important supervisory executive network.  
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IV. Progression in prediagnostic Huntington disease 
 
A. Introduction 
 
Huntington disease (HD) is an autosomal dominant disorder characterized by progressive 
decline of motor, cognitive, and behavioral function. The disease-causing mutation is a 
trinucleotide (CAG) repeat expansion in the 5’ translated region of the huntingtin gene.1 
The average age of onset is 40 years, although onset occurs as early as age 2 and as late 
as age 80.
81;82
  
 
Disease onset is insidious, often with a long prediagnostic period prior to the clinical 
diagnosis. Typically, diagnosis is made based on the presence of unequivocal motor signs 
consistent with HD. Unfortunately, there are no current pharmacologic or therapeutic 
interventions shown to delay or slow the onset or progression of HD. Therefore, it is 
essential that sensitive and specific biomarkers in the prediagnostic period be identified 
that could be used to evaluate future therapeutic interventions.  
 
Several studies have sought to identify potential prediagnostic biomarkers. Some cross 
sectional studies reported prediagnostic CAG expanded individuals (CAG+) exhibited 
deficits in tests of attention,
300
 executive function,
301;302
 memory,
131;300;301;303;304
 
psychomotor speed,
131;300
 and ocular movements;
111;119;120;122;306
 however, other studies of 
these same domains have not confirmed these results.
128;312;379-383
 In a large cross 
sectional sample of 438 prediagnostic individuals, Paulsen and colleagues
100
 reported the 
commencement of detectable changes begins one to two decades prior to the estimated 
age of onset, and this initial period is followed by more rapid change in the years just 
prior to diagnosis. Few studies have explored longitudinal rates of decline in 
prediagnostic CAG+ individuals. There have been reports of differential rates of 
progression between prediagnostic CAG+ and nonexpanded (CAG-) controls in measures 
of attention, psychomotor speed, and memory;
130;307-310
 however, others have not been 
able to replicate these results.
311-314
 These discrepant results may be due to the modest 
sample sizes of most studies.  
  
61 
 
The goal of this study was to examine longitudinal rates of change in a sample of at-risk 
individuals for a series of neurocognitive, psychomotor, and oculomotor measures. We 
use estimated time to onset in two ways: 1) as a continuous variable to evaluate change 
within a group of CAG+ individuals, and 2) as a means of dichotomizing a group of 
CAG+ individuals (into those Near and Far from onset) in order to compare the rate of 
decline in each with the rate in CAG- individuals. We hypothesize that the rate of 
progression is not uniform within the prediagnostic period and that it increases as CAG+ 
individuals approach onset. In addition, the rate of change is faster in CAG+ than in 
CAG- individuals. 
 
B. Methods 
 
1. Participants 
  
Participants were recruited primarily through the National Research Roster for 
Huntington Disease Patients and Families (HD Roster). The inclusion criteria were: 1) a 
parent diagnosed with HD; 2) between the ages of 18 and 65; and 3) a non-diagnostic 
motor exam at the first study visit (Unified Huntington Disease Rating Scale-99
87
 
(UHDRS) diagnostic confidence level less than 4). All participants completed two study 
visits, approximately 2.5 years apart. The testing protocol was identical at both visits. 
Medical history, current medications, and history of alcohol and recreational drug use 
were collected at both visits. Any participants reporting a concurrent neurologic illness, 
major psychiatric diagnosis (e.g. schizophrenia, bipolar disorder), or current alcohol or 
drug abuse were excluded from the analyses. Participants were asked not to disclose their 
CAG status, if known, to study staff. This study was approved by the local institutional 
review board (IUPUI IRB Study No. 0109-12). All participants provided written 
informed consent. 
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2. Clinical Evaluation and Study Group Assignment 
 
Molecular testing of the huntingtin gene was performed
317
 to determine the number of 
CAG repeats. Normal controls (NC; n=68) were defined as those having 2 unexpanded 
alleles (<28 CAG repeats). Individuals with at least 1 expanded allele (>38 CAG repeats) 
were considered CAG expanded (CAG+; n=39). Subjects whose larger allele contained 
28 to 38 CAG repeats, inclusive, were considered inconclusive and were not used in the 
analyses (n=10).  
 
Two movement disorder neurologists (J.W., X.B.) administered the motor exam portion 
of the UHDRS. Both were aware that the participants were at-risk for HD, but were 
blinded to the results of all other study assessments, including the results of huntingtin 
gene testing. The motor examination was performed for each participant at both study 
visits. On the basis of the motor examination only, they assigned an overall confidence 
rating which represented the likelihood that any observed abnormalities represented HD. 
The ratings were defined as: (0) normal (no abnormalities); (1) nonspecific motor 
abnormalities (less than 50% confidence); (2) motor abnormalities that may be signs of 
HD (50% to 89% confidence); (3) motor abnormalities that are likely signs of HD (90% 
to 98% confidence); and (4) motor abnormalities that are unequivocal signs of HD (≥99% 
confidence). CAG+ subjects with a confidence rating from 0-3 at their second visit were 
considered prediagnostic (n=34). Five subjects who were prediagnostic at their first visit 
became diagnostic (confidence rating of 4) at their second visit. Estimated onset was 
defined as the age at which a person had a 50% probability of having manifest disease, 
and the estimated time to onset
84;100
 (TTO) was calculated for each participant at each 
study visit. The distribution of TTO at the first study visit was reviewed and one subject 
was removed due to a very large TTO (>3.5 SD from the mean) so that 38 CAG+ 
subjects were included in the analyses.  
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3. Study Assessment 
 
The study battery included an assessment of neurocognitive performance, psychomotor 
speed, and saccadic eye movements. All testing was conducted in a private examination 
room by trained study staff. 
 
Neurocognitive performance and psychomotor speed were evaluated using measures 
from six tests: 1) Wechsler Adult Intelligence Scale-Revised
348
 (WAIS-R): Arithmetic, 
Picture Arrangement, and Digit Symbol subtests; 2) Stroop Color-Word Interference 
Task:
350
  Word Reading, Color Naming, Interference; 3) Trail Making Test:
384
 Parts A 
and B; 4)  WAIS-III:
385
 Letter-Number Sequencing Test; 5) California Verbal Learning 
Test
137
 (CVLT): Total Learning, Semantic Clustering, Short Delay Recall, Long Delay 
Recall, Recognition Discriminability; 6) H-scan system:
351
 reaction time (RT) (Auditory 
RT, Visual RT, Decision RT) and motor speed (Movement Time (MT), Decision MT, 
Alternate Button Tapping). We also assessed depressive symptomatology using the 
Center for Epidemiologic Studies Depression Scale (CES-D).  
 
Saccadic eye movement testing was performed as described previously.
119
 Briefly, the 
participant was seated 1 meter from a large white screen in front of a bar with vertical 
and horizontal target lights (light-emitting diodes, LED). Three saccadic tasks were 
administered: anti-saccade (AS), memory guided, simple version (MG1), and memory 
guided, complex version (MG2). The vertical and horizontal positions of the participant’s 
pupils were recorded binocularly with two ultra-miniature high-speed (250 Hz) video 
cameras attached to a headband and digitized at 250 Hz for later analysis (Eyelink II, SR 
Research Ltd, spatial resolution < 0.1 degree). Before each task, the examiner instructed 
the participant verbally to ensure that the participant understood the instructions. Each of 
the tasks consisted of 25 trials. After the participant completed the testing procedure, an 
interactive computerized analysis
122
 of the right eye position was performed. Current 
analyses focused on the AS and MG measures (saccadic latency, the standard deviation 
of saccade latency, and percentage of errors) previously reported to demonstrate 
abnormalities in prediagnostic HD.
119
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4. Statistical Analysis 
 
We tested for group differences in depression at each visit using a Fisher’s exact test. All 
analyses evaluated the change in the performance of neurocognitive, psychomotor, and 
oculomotor tasks between the two study visits in the NC and prediagnostic CAG+ 
participants.  
 
To evaluate longitudinal change during the prediagnostic period, we analyzed 
neurocognitive, psychomotor, and oculomotor performance using a repeated measures, 
mixed linear model (SAS v9.13). The model included three terms: 1) a main effect of 
TTO, indicating a linear relationship between TTO and performance; 2) a main effect of 
visit, indicating a change in performance between the study visits, and perhaps indicating 
either training/learning or disease progression between the visits; and 3) an interaction 
between TTO and visit, indicating an effect of TTO on the between-visits change in 
performance. The model also included age, sex, and education as covariates, when there 
was a significant effect (p≤0.05). This analysis included only prediagnostic CAG+ 
participants. 
 
We also evaluated how the rate of change in prediagnostic CAG+ subjects compared with 
that in CAG- subjects. To do this, a median split in the TTO distribution was used to 
define two prediagnostic groups: 1) Far from onset (Far), defined as those participants 
whose TTO at the first study visit was greater than 11 years (n=19); and 2) Near to onset 
(Near), defined as those participants whose TTO was less than 11 years (n=19). 
 
The rate of change in the prediagnostic (CAG+) and NC (CAG-) groups for each study 
measure was calculated for each participant as follows:  
 
rate = (visit 2 measure – visit 1 measure) / months between visits. 
 
These rates were analyzed using analysis of covariance (ANCOVA) to test for group 
effects (3 groups: NC, Far, Near) with sex, age, and education as covariates. For variables 
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with a significant group effect (p≤0.05), post hoc analysis was performed using two-sided 
t-tests of all pairwise comparisons.  
 
For all analyses we employed a nominal significance value (p≤0.05). We recognize that 
we are testing multiple outcomes; however, our approach was to review results to identify 
trends or domains consistently affected in prediagnostic individuals. 
 
C. Results 
 
The 106 participants included in the analysis completed two visits approximately 2.5 
years apart (28.6 ± 5.2 months). The three groups (NC, Far, Near) did not differ 
significantly (p≥0.6) for sex, race, handedness, education, or months between study 
visits, nor was there a significant difference (p=0.1) between the Near and Far groups for 
the number of CAG repeats (Table 9). The groups did, however, differ significantly for 
age (p=0.02), with the Far group being significantly younger than the other two groups 
(Table 9). Due to technical difficulties, saccade tasks were completed in only a subset of 
the participants (n=74). The prevalence of depression was assessed in our patients using 
the CES-D. At the first study visit, there was no significant difference between the NC, 
Table 9. Participant demographics. 
 
 NC Far Near 
Number of participants 68 19 19 
Age at first visit
a
 (years) 45.2±8.7 39.5±9.2 47.7±10.8 
Months between visits
a
 28.2±4.1 29.5±7.0 29.1±6.6 
Education
a
 (years) 15.6±2.8 15.5±1.9 15.6±3.4 
Male:Female 19:49 6:13 7:12 
Race (% Caucasian) 98.5% 100% 100% 
Handedness (% right) 91.2% 89.5% 89.5% 
CAG repeats
a
  41.7±2.7 43.4±4.0 
Estimated time to onset computed 
from first visit
a
 (years) 
18.2±4.7 8.1±1.7 
a
 Mean  SD 
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Far, and Near groups (p=0.4). At the second visit, the prevalence was significantly higher 
in the Far group (p=0.01). 
 
1. Repeated Measures Analysis in CAG+ Individuals 
 
Repeated measures analysis was used to examine the main effects of TTO and visit, and 
the interaction between the two on each of the performance outcomes. Representative 
plots of the data are shown in Figure 9. Each subject’s performance at the first and 
second visits is connected by a line. For alternate button tapping (Figure 9A), a 
significant main effect of TTO indicated that subjects require more time to complete 30 
round trips as they approach onset. A similar trend is not seen for variability of latency of 
MG1 (Figure 9C) or for percentage of errors of MG2 (Figure 9E), indicating no 
significant effect of TTO. The interaction between TTO and visit can be seen by 
examining the changes from visit 1 to visit 2. For alternate button tapping (Figure 9A) the 
changes for subjects with a larger estimated TTO tend to be relatively flat, and become 
steeper as onset approaches. For variability of latency of MG1 and the percentage of 
errors of MG2 (Figure 9, panels C and E), the changes for subjects with a larger 
estimated TTO suggest improvement or learning from the first to second visit, while the 
changes for subjects with a smaller estimated TTO suggest a failure to learn from the first 
visit or reduction in performance that cannot be compensated for with learning effects. To 
facilitate visualization of the interaction, the slope of the line in Figure 9A, C and E has 
been plotted as a single point for each subject in Figure 9, panels B, D, and F, 
respectively.  
 
The results of the repeated measures analysis are shown in Table 10. A significant main 
effect of TTO (p≤0.04) was found for subtests of the H Scan (audio and visual RT, MT, 
decision MT, and alternate button tapping), WAIS (picture arrangement, digit symbol, 
and letter number sequencing), CVLT (long delay recall), Stroop (color naming, word 
reading, and interference), Trail Making (Part A), and the AS task (percentage of errors). 
In all cases, performance was worse in subjects with a smaller TTO than in those with a 
larger TTO. A significant main effect of visit (p≤0.05) was found for subtests of the H 
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Scan (alternate button tapping), WAIS (picture arrangement), the MG1 task (percentage 
of errors, latency, and variability of latency), and the MG2 task (percentage of errors). Of 
these measures, only picture arrangement demonstrated an overall improvement at the 
second visit, indicating a learning effect. Performance on the other tests with a significant 
visit effect was worse at the second visit. A significant interaction between TTO and visit 
(p≤0.02) was found for subtests of the H Scan (MT and alternate button tapping), the 
MG1 task (variability of latency), and the MG2 task (percentage of errors). For all four 
measures, the rate of decline was more rapid as subjects approached onset. 
 
2. ANCOVA in CAG+ and CAG- Individuals 
 
ANCOVA was used to test for differences in the rate of change between NC, Far, and 
Near groups. Table 11 shows the raw group means and the p values adjusted for 
covariates. Significant group differences (p≤0.03) were found for 3 measures from the H-
Scan (audio and visual RT, and alternate button tapping). For all three measures, post hoc 
testing demonstrated that the rate of change was significantly greater (p≤0.007) for the 
Near group as compared with the NC. Furthermore, a significantly faster rate of change 
was found in the Near group as compared with the Far group (p=0.007) for alternate 
button tapping. For the saccadic tasks, all measures from the MG1 task (percentage of 
errors, latency, and variability of latency) and the percentage of errors from the MG2 task 
also yielded significant group effects (p≤0.03). Subsequent post-hoc testing found that 
the rate of change was significantly faster in the Near group as compared with the NC 
group (p≤0.008) for all but the variability of latency of MG1, though a trend was also 
found for this measure (p=0.055). Furthermore, the rate of change was faster in the Near 
group as compared with the Far group (p=0.04) for all but the percentage of errors of 
MG1. Additionally, the Far group declined faster than the NC for the percentage of errors 
of MG1 (p=0.02). No other study measure showed a significant group effect for the rate 
of change. 
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Figure 9. Performance of CAG+ subjects. Progression is shown both by connecting a 
subject’s performance at each study visit with a  line vs. TTO at each visit (A,C,E) and as 
the change in performance/TTO year vs. TTO at the first study visit (B,D,F). A,B: 
Alternate Button Tapping; C,D: Variability of latency of MG1; E,F: Percentage of Errors 
of MG2. 
 
A. 
 
 
 
B. 
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Figure 9. Performance of CAG+ subjects. Progression is shown both by connecting a 
subject’s performance at each study visit with a  line vs. TTO at each visit (A,C,E) and as 
the change in performance/TTO year vs. TTO at the first study visit (B,D,F). A,B: 
Alternate Button Tapping; C,D: Variability of latency of MG1; E,F: Percentage of Errors 
of MG2. 
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Figure 9. Performance of CAG+ subjects. Progression is shown both by connecting a 
subject’s performance at each study visit with a  line vs. TTO at each visit (A,C,E) and as 
the change in performance/TTO year vs. TTO at the first study visit (B,D,F). A,B: 
Alternate Button Tapping; C,D: Variability of latency of MG1; E,F: Percentage of Errors 
of MG2. 
 
E. 
 
 
 
F. 
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Table 10. Results of repeated measure mixed model. 
 
TTO Visit TTO*Visit 
H Scan 
   
Audio Reaction Time 0.01 NS
1
 NS 
Visual Reaction Time 0.004 NS NS 
Decision Reaction Time NS NS NS 
Movement Time 0.0007 NS 0.009 
Decision Movement Time 0.0003 NS NS 
Alternate Button Tapping 0.005 0.02 0.02 
WAIS-R/WAIS III 
   
Arithmetic NS NS NS 
Picture Arrangement 0.02 0.05 NS 
Digit Symbol 0.02 NS NS 
Letter Number Sequencing 0.03 NS NS 
CVLT 
   
Total Learning NS NS NS 
Semantic Clustering NS NS NS 
Short Delay Recall NS NS NS 
Long Delay Recall 0.04 NS NS 
Recognition Discriminability NS NS NS 
Stroop 
   
Color Naming 0.004 NS NS 
Word Reading 0.004 NS NS 
Interference 0.04 NS NS 
Trail Making Test 
   
Part A 0.02 NS NS 
Part B NS NS NS 
Anti-Saccade 
   
Percentage of Errors 0.0001 NS NS 
Latency NS NS NS 
Variability of Latency NS NS NS 
1 NS = not statistically significant (p>0.05) 
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Table 10. Results of repeated measure mixed model. 
 
TTO Visit TTO*Visit 
 
Memory Guided 1 
   
Percentage of Errors NS
 
0.05 NS 
Latency NS 0.03 NS 
Variability of Latency NS 0.005 0.01 
Memory Guided 2 
   
% of Errors NS 0.0003 0.0008 
% of Missed Flashes NS NS NS 
1 NS = not statistically significant (p>0.05) 
 
  
 
7
3
 
Table 11. Results of ANCOVA with three groups. 
 
 Mean ± SD  p-values 
H Scan NC Far Near  Group 
NC vs. 
Far 
NC vs. 
Near 
Far vs. 
Near 
Audio Reaction Time -0.00038 ± 0.00077 -0.00022 ± 0.00062 0.00031± 0.0012  0.007 0.4 0.002 0.06 
Visual Reaction Time -0.00016 ± 0.00064 5.8E-05 ± 0.00067 0.00029 ± 0.00094  0.03 0.5 0.007 0.1 
Alternate Button 
Tapping 
-0.011 ± 0.076 -0.0042 ± 0.063 0.053 ± 0.13 
 
0.005 0.7 0.002 0.007 
Memory Guided 1         
Percentage of Errors -0.20 ± 0.40 0.34 ± 0.78 0.53 ± 0.87  0.005 0.02 0.003 0.5 
Latency -0.015 ± 1.94 0.26 ± 2.41 2.19 ± 3.13  0.03 0.8 0.008 0.04 
Variability of 
Latency 
0.47 ± 2.55 -0.13 ± 2.38 1.91 ± 2.77 
 
0.03 0.2 0.055 0.01 
Memory Guided 2         
% of Errors -0.036 ± 1.16 -0.25 ± 1.16 0.86 ± 0.92  0.01 0.9 0.006 0.01 
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D. Discussion 
 
The identification of potential biomarkers of disease progression in prediagnostic HD is a 
largely unmet requisite for performing neuroprotective drug trials in CAG+ individuals. 
We have used two complementary approaches to examine longitudinal changes in 
prediagnostic CAG+ subjects, and to compare these changes between CAG- and CAG+ 
subjects. 
 
Initial analyses using a repeated measures model with only prediagnostic CAG+ subjects 
confirmed that performance on a number of neurocognitive, psychomotor, and 
oculomotor tests declines during the prediagnostic period. The results from this study 
indicate that psychomotor measures (H Scan subtests, digit symbol) are particularly 
sensitive, and that certain neurocognitive and oculomotor measures are also sensitive to 
declining performance in the prediagnostic period.  
 
The central hypothesis of the study was that the rate of decline in functioning increases as 
subjects approach estimated disease onset. This hypothesis was addressed through the 
interaction term: TTO x visit. Four subtests (MT, alternate button tapping, variability of 
latency of MG1, and percentage of errors of MG2) were able to detect a significant 
change in the rate of decline as subjects approach onset. In all cases, the rate of decline 
increased as the subjects approached their estimated age of onset. Our results also 
emphasize the importance of longitudinal studies. For variability of latency of MG1 and 
percentage of errors of MG2, no cross sectional effect of TTO was detectable. However, 
it is clear that longitudinal performance changes as subjects approach onset for these two 
measures. Subjects with a larger estimated TTO tend to perform slightly better at their 
second visit, indicating a training or learning effect; but those with a smaller estimated 
TTO perform worse at their second visit, suggesting that they no longer benefit from 
having done the task previously. It is also noteworthy that all of the measures with a 
significant TTO x visit interaction have a motor component, suggesting that motor 
measures (with or without a cognitive component) may be the most sensitive to detect 
rate differences during the prediagnostic period. 
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We also tested the hypothesis that the rate of decline is different between CAG- and 
CAG+ subjects. The CAG+ subjects were dichotomized into either a Far from or Near to 
onset group. Of the seven subtests with a significant ANCOVA test (p≤0.05), post hoc 
tests revealed a difference between the NC and Near groups for six of the subtests. For 
the seventh subtest (variability of latency of MG1), a trend was also found (p=0.055). 
Only the percentage of errors of MG1 was sufficiently sensitive to detect a difference 
between the NC and Far groups. Interestingly, this measure did not detect a significant 
difference in the rate of decline during the prediagnostic period using either method, 
suggesting that the rate of change is different between CAG- and CAG+ subjects but that 
the rate is constant throughout the prediagnostic period.  
 
ANCOVA confirmed the results from the repeated measures analysis that supported a 
changing rate of decline during the prediagnostic period for alternate button tapping, 
variability of latency of MG1, and percentage of errors of MG2. The only discrepancies 
between the two methods were with MT and latency of MG1. Further examination of 
these data suggests that a difference in the rate of decline in MT is subtle and that 
dichotomization of the sample increased variability so that differences could not be 
detected. On the other hand, it appears that the significant difference found in latency of 
MG1 is likely due to a few subjects, and a larger sample may be required to have 
sufficient power to test this hypothesis. 
 
These results provide a functional correlate to longitudinal anatomical findings. Aylward 
et al.
171
 reported significantly smaller striatal volume cross sectionally in subjects up to 
20 years before onset; however, the rate of striatal atrophy was significantly increased 
only 10 years prior to onset. Many previous cross sectional studies detected performance 
differences during the prediagnostic period;
100;111;119;120;122;131;300-304;306
 however, fewer 
longitudinal studies have been performed and differences in the rate of change during the 
prediagnostic period have not been consistently reported.
130;307-314
 Our data would appear 
to suggest that the differences in rates are subtle but can be detected with particular 
measures. As seen from the ANCOVA, the most significant differences in rate of change 
are between the NC and Near groups, indicating that the most rapid decline occurs close 
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to onset. Furthermore, by directly plotting the rate of change for each subject against 
TTO at the first visit (Figure 9), it appears that for alternate button tapping and the 
percentage of errors of MG2 the rate of decline increases only as subjects are within 
approximately 10 years of their estimated age of onset. However, for the variability of 
latency of MG1 the rate of decline appears to increase earlier in the prediagnostic period. 
Further work is required to see if this pattern is consistent, but it may indicate that 
saccadic measures are more sensitive in detecting differences in rate of change early in 
the prediagnostic period; however, they may not be more sensitive than other measures 
when examining the entire prediagnostic period. 
 
While in many instances CAG+ individuals further from their estimated onset do not 
appear to decline more rapidly than CAG-, this does not imply an absence of pathology. 
Others have noted the likelihood of compensatory mechanisms sufficient to mask the 
behavioral effects of underlying pathology early in the prediagnostic period. This study 
does not use methods to investigate underlying neural integrity (e.g. MRI, fMRI, EEG, 
etc.) and thus cannot test whether there is an absence of pathology in our subjects or 
neuronal compensation that masks pathological changes. 
 
This study had several strengths and weaknesses. One strength was that all study 
participants had a parent with HD and thus were at-risk for HD. This generates groups 
that have greater matching for unmeasurable factors as compared to a study in which the 
CAG- group is not at-risk for HD. In addition, all subjects completed a uniform study 
visit that evaluated a number of domains reported to be affected early in disease 
progression. The study also had several weaknesses. The size of the sample is similar to 
that of previous studies but is still relatively modest to detect small differences in rates of 
change. Furthermore, the sample of CAG+ individuals tended to have a smaller number 
of expanded repeats with fewer subjects having greater than 50 repeats. As a result, we 
have limited power to test whether those with a larger number of CAG repeats (i.e. >50 
CAG) have more rapid rates of decline as compared with those having the more typical 
number of repeats (39-50 CAG repeats). We collected data regarding depression using 
the CES-D and found that depressive symptomology was significantly higher in the Far 
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group than the other two groups at the second visit. One possible explanation may be that 
as subjects approach onset (Near group), the depressive symptoms worsen and they seek 
medical attention to alleviate its effects. Unfortunately, we were not able to assess this 
explanation because we did not ask subjects if they had sought out medical care for 
depression. Finally, both a strength and a weakness of the study was that the CAG+ 
individuals were distributed throughout the prediagnostic continuum as estimated by their 
TTO. This allowed the use of TTO as a continuous variable and evaluated a linear 
relationship between TTO and performance; however, it also likely resulted in extensive 
heterogeneity within each group when the CAG+ participants were divided into Near and 
Far groups. 
 
We are currently collecting data for a third time point in these subjects. We will evaluate 
whether these new data provide improved model fitting to better estimate the rate of 
disease progression across study variables in a sample of subjects who are either 
prediagnostic or in the early stages of clinically diagnosable disease. We anticipate that 
these data will further improve our ability to identify sensitive and specific biomarkers in 
the early stages of disease progression.  
 
  
  
78 
 
V. Summary 
 
Many studies have examined the changes that take place in premanifest HD, and it is 
clear that motor,
98-100;118;131;300;306
 ocular motor,
98;99;111;119;120;122;306
 cognitive,
99;131;157;300-
305;383
 and behavioral abnormalities can be reliably detected.
151;161;309;341;386
  Furthermore, 
imaging studies have shown striatal and extra-striatal gray matter 
changes
100;101;171;174;175;182-186;188-192;195;196;316
 and white matter abnormalities
184;196;316;334;387-
390
 during the premanifest period of the disease. Taken together, this is overwhelming 
evidence that neurodegeneration begins many years prior to diagnosis of HD. 
 
The current standard of therapy for HD is to manage the symptoms of the disease, though 
this strategy has limited success.
391
  Neuroprotective intervention promises to slow the 
rate of progression and delay or even prevent disease onset. It would ideally occur during 
the premanifest period before quality of life is adversely and irreparably affected. A 
significant challenge to evaluating neuroprotective therapies in premanifest HD is that the 
only acceptable endpoint for regulatory agencies is disease onset; Hersch and Rosas
392
 
suggest that a study using this endpoint would require up to 3000 subjects and 6 years of 
follow-up to detect a 40% decline in the frequency of onset. One strategy to avoid such 
costly and unreasonable studies is to evaluate a therapy in both manifest HD using 
regulatory agency-acceptable outcomes and in premanifest HD using biomarkers of 
progression. The hope is that demonstration of efficacy in manifest HD combined with 
premanifest biomarker improvement would be sufficient to gain regulatory approval, 
though this method has not yet been tried.
392
 
 
The work presented herein further establishes saccades as effective measures of 
premanifest disease progression. In response to previous work showing the cross 
sectional sensitivity of saccadic measures, we decided to further characterize the nature 
of saccades in HD by investigating the neural correlates of saccade impairment and the 
longitudinal progression of saccadic measures in premanifest HD. This work has shown 
that saccadic impairment is associated with cortical and subcortical atrophy, that 
identifiable functional brain changes underlie saccade impairment, and that saccade 
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performance decline can be detected over a relatively short period of time in premanifest 
HD. 
 
Because of the early and extensive atrophy that occurs in the striatum, many attempts 
have been made to interpret cognitive and motor abnormalities in the context of striatal 
atrophy. Indeed, it has been hypothesized that degeneration in the putamen is associated 
with motor deficits, while degeneration in the caudate is associated with cognitive 
deficits.
170
  This is supported by imaging studies reporting that putamen atrophy was 
associated with atrophy in cortical regions that make up the motor cortico-striatal loop, 
and caudate atrophy with those that make up the cognitive part of the loop.
193
  While it is 
impossible to completely separate the striatum from cortical regions given the density of 
neuronal connections between the two, our findings suggest that cortical and striatal 
atrophy contribute to saccade dysfunction in a non-redundant manner. The AS task in 
particular appears well suited for evaluating cortical changes; AS performance is 
associated with gray matter loss in SFG and IPL, and there is a strikingly absent BOLD 
response in ACC and pre-SMA following AS errors. It is likely that saccades are not 
unique in this regard and that cortical changes also contribute to other signs and 
symptoms of the disease. 
 
Further studies are needed in order to better understand the connection between brain 
pathology and saccade performance. In particular, whole-brain rather than ROI-based 
approaches provide an opportunity to discover truly unexpected findings. While an ROI 
approach is helpful in that it reduces the number of potentially spurious and biologically 
implausible findings, it also constrains the conclusions that can be drawn. For example, 
based on our study design we were able to discuss abnormalities in our a priori ROIs, but 
could not make any conclusions regarding functional compensation outside of these ROIs 
as others have done.
202;393
  These studies should also be carried out longitudinally, as 
evidence of co-decline will strengthen the likelihood of causative relationships between 
atrophy and saccade decline. Another imaging method with great potential is the use of 
diffusion tensor imaging (DTI). This method relies on the diffusion characteristics of 
water to examine microstructural changes, including the integrity of fibers connecting 
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discrete regions. The use of DTI in studying HD is growing, and one study has shown a 
negative association between fiber tract integrity connecting FEF and caudate and the 
variability of latency of voluntary saccades. Being able to link gray matter atrophy, 
functional abnormalities, and white matter tract integrity should provide important 
insights to the nature of saccade, cognitive, and motor dysfunction in HD. 
 
Previous studies identified saccades as potential biomarkers of premanifest disease 
progression,
111;119;120;122
 and our imaging studies have provided biological insight into the 
underlying neural mechanisms of impairment. A longitudinal study was conducted to 
further explore the potential of saccadic measures as biomarkers. This study confirmed 
impairment in premanifest HD and provided the first look at the longitudinal behavior of 
saccades in this population. Not surprisingly, we found different patterns of decline. 
Some measures declined constantly in premanifest HD, though more rapidly in CAG+ 
than in CAG-. These measures would be useful in clinical trials to evaluate the 
effectiveness of a therapy to slow disease progression. Another pattern of decline was one 
in which the rate of decline increased just prior to disease onset. One possible explanation 
is that some additional disease process is triggered, leading to more rapid decline. 
Another explanation is that, prior to this increase, compensatory mechanisms attenuated 
decline, but that a critical threshold was reached, beyond which compensation was no 
longer effective. Measures with this pattern of decline could be used to evaluate the 
ability of an intervention to prevent a disease-augmenting trigger or to facilitate 
compensation. Importantly, these changes could be detected over a relatively short period 
of time. However, still more work needs to be done to longitudinally characterize 
saccades. More time points are needed to confirm the findings described above. 
Furthermore, examination over a shorter time period would be helpful to determine the 
minimum length of a clinical trial in which saccades could be useful. 
 
While studies have consistently confirmed the potential of saccades to track premanifest 
disease, technological advancements have also taken place that make the wide-spread use 
of quantitative saccades possible.
120
  Scleral search coils are still considered the gold 
standard for quantitatively measuring eye movements, but they are slightly invasive and 
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can lead to discomfort, increased intraocular pressure, and temporary reduction in visual 
acuity.
394
  We used a non-invasive, high-frequency video-recording system, but 
widespread use of such a system is limited by both its cost and, more importantly, its 
relative immobility. Fortunately, the newly developed systems mentioned above are non-
invasive, and their ease-of-use and portability make adoption in a clinical setting much 
more likely. 
 
In addition to saccades, other measures will likely be included in a battery to follow 
disease progression. Structural MRI, particularly of the striatum, would be a good fit 
given the extensive characterization that is already in place. Qualitative assessment of the 
striatum seems unlikely to be sufficiently sensitive, so quantitative measurements must be 
made. While such measurements previously required extensive human effort, the 
methods that we employed use computer processing capabilities to reduce human time 
involvement. Furthermore, these methods remove inter-rater variability by using a 
standard algorithm to define structures. A third measure that would almost certainly be 
included in such a battery would be speeded or self-paced finger tapping. Both of these 
have been repeatedly shown to be quite sensitive in the premanifest period,
98-100
 and there 
is fMRI evidence of neural substrates for this impairment
198
 (Table 2). 
 
The relative temporal appearance of disease-related changes is an important question, but 
one that is not often addressed explicitly in published studies partly because the sample 
sizes for such an assessment would need to be quite large. However, the results that have 
been published allow for some speculation on the matter. It appears that striatal atrophy is 
among the earliest detectable changes; it has been found up to 20 years prior to estimated 
disease onset
171
 (Figure 10). Motor impairment, including speeded and self-paced finger 
tapping,
100
 and incorrect and slowed saccades (unpublished data) appears to be present 
10-15 years prior to onset. Cognitive impairment, while detectable in premanifest disease, 
appears to onset around 10 years prior to onset.
100
  Psychiatric manifestations of the 
disease, while prevalent, do not follow a prescribed time course, nor do they progress 
with other disease-related impairment.
86
  The fMRI findings described above are 
interesting in that none of the premanifest CAG+ subjects had normal activation in 
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response to AS errors even 
though they were predicted to be 
as much as 18 years prior to 
disease onset. While these 
functional changes may be some 
of the earliest that can be 
detected, more studies are needed 
to confirm these initial findings.  
 
There are many reliable 
measures of impairment and 
disease progression during 
premanifest HD, but it is unlikely 
that one measure will be 
sufficient to track progression throughout the disease continuum. For example, we have 
seen that the percentage of errors during MGc is sensitive early in premanifest disease but 
that individuals with manifest disease often complete only a few correct trials, suggesting 
a limiting floor effect of the task. On the other hand, cognitive measures may not be as 
sensitive during the earliest periods, but they may have utility further into the manifest 
disease range. Because these measures will be used to evaluate therapeutic efficacy in 
clinical trials, longitudinal characterization will inform a selection of measures that are 
able to capture a wide range of disease progression. 
 
While prevention remains the ultimate goal of therapy in HD, there are significant 
obstacles that must be overcome. First, prevention will require correcting the pathogenic 
nature of mutant huntingtin, yet there are many fundamental questions that remain 
regarding the pathogenesis of the disease. Second, the disease is clearly progressive and 
begins many years before a clinical diagnosis can be made. Given the protein’s 
ubiquitous expression throughout both development and the body, it is not unreasonable 
to expect that as yet unidentified pathology exists from birth or even earlier. It is in this 
Table 10. Temporal appearance of changes in 
premanifest HD. Striatal atrophy is one of the 
earliest detectable changes in premanifest HD, 
with motor and cognitive impairment following. 
Psychiatric manifestations vary in their temporal 
appearance. Prelminary fMRI studies indicate 
early activation abnormalities in response to 
errors, though more study is necessary. 
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sense that Hersch and Rosas
392
 argue that neuroprotective therapy in HD is inherently not 
preventative. 
 
Neuroprotective therapy that delays disease onset seems to be a more attainable goal, at 
least in the short term. Intervention would begin during the premanifest period of the 
disease. Given our current understanding of premanifest disease progression, the above-
mentioned evaluative battery consisting of quantitative saccades, finger tapping, and MRI 
would inform physicians regarding the earliest signs of the disease. Therapy would begin 
with these earliest signs of the disease, probably 10-15 years prior to predicted onset, in 
order to preserve quality of life. Although it is tempting to intervene even earlier, there 
are important considerations that temper the ―earlier is better‖ approach. For example, it 
is impossible to establish therapeutic efficacy before the presence of any signs or 
symptoms of the disease, underscoring the importance of identifying early markers of 
disease progression. In fact, efficacy is probably the most important of these 
considerations because it is central to other discussions of therapeutic and financial cost-
benefit analyses. Furthermore, I am hopeful that development and implementation of 
effective neuroprotective therapies will also lead to a better understanding of the disease, 
which in turn will increase our ability to identify earlier disease processes, thus providing 
the opportunity to intervene even earlier.  
 
While not prevention, I believe that the development of these neuroprotective 
interventions could have effects extending beyond simply delaying onset. More people 
may seek presymptomatic gene testing if a disease-altering therapy is available, though 
predicting responses to gene testing is notoriously imprecise in HD.
8;10
  Assuming that 
presymptomatic testing does increase, the associated counseling and family planning 
combined with delayed onset could have important consequences on the future 
prevalence of the disease.  
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